GebFra Science | Guideline
Interdisciplinary Screening, Diagnosis, Therapy and Follow-up
of Breast Cancer. Guideline of the DGGG and the DKG
(S3-Level, AWMF Registry Number 032/045OL, December 2017) –
Part 2 with Recommendations for the Therapy of Primary,
Recurrent and Advanced Breast Cancer
Interdisziplinäre Früherkennung, Diagnostik, Therapie und
Nachsorge des Mammakarzinoms. Leitlinie der DGGG und DKG
(S3-Level, AWMF-Registernummer 032/045OL, Dezember 2017) –
Teil 2 mit Empfehlungen zur Therapie des primären,
rezidivierten und fortgeschrittenen Mammakarzinoms
Authors
Achim Wöckel 1, Jasmin Festl 1, Tanja Stüber 1, Katharina Brust 1, Mathias Krockenberger 1, Peter U. Heuschmann 2,
Steffi Jírů-Hillmann 2, Ute-Susann Albert 3, Wilfried Budach 4, Markus Follmann 5, Wolfgang Janni 6, Ina Kopp 3,
Rolf Kreienberg 6, Thorsten Kühn 7, Thomas Langer 5, Monika Nothacker 3, Anton Scharl 8, Ingrid Schreer 9, Hartmut Link 10,
Jutta Engel 11, Tanja Fehm 12, Joachim Weis 13, Anja Welt 14, Anke Steckelberg 15, Petra Feyer 16, Klaus König 17,
Andrea Hahne 18, Traudl Baumgartner 18, Hans H. Kreipe 19, Wolfram Trudo Knoefel 20, Michael Denkinger 21,
Sara Brucker 22, Diana Lüftner 23, Christian Kubisch 24, Christina Gerlach 25, Annette Lebeau 26, Friederike Siedentopf 27,
Cordula Petersen 28, Hans Helge Bartsch 29, Rüdiger Schulz-Wendtland 30, Markus Hahn 22, Volker Hanf 31, Markus MüllerSchimpfle 32, Ulla Henscher 33, Renza Roncarati 34, Alexander Katalinic 35, Christoph Heitmann 36, Christoph Honegger 37,
Kerstin Paradies 38, Vesna Bjelic-Radisic 39, Friedrich Degenhardt 40, Frederik Wenz 41, Oliver Rick 42, Dieter Hölzel 11,
Matthias Zaiss 43, Gudrun Kemper 44, Volker Budach 45, Carsten Denkert 46, Bernd Gerber 47, Hans Tesch 48,
Susanne Hirsmüller 49, Hans-Peter Sinn 50, Jürgen Dunst 51, Karsten Münstedt 52, Ulrich Bick 53, Eva Fallenberg 53,
Reina Tholen 54, Roswita Hung 55, Freerk Baumann 56, Matthias W. Beckmann 57, Jens Blohmer 58, Peter Fasching 57,
Michael P. Lux 57, Nadia Harbeck 59, Peyman Hadji 60, Hans Hauner 61, Sylvia Heywang-Köbrunner 62, Jens Huober 6,
Jutta Hübner 63, Christian Jackisch 64, Sibylle Loibl 65, Hans-Jürgen Lück 66, Gunter von Minckwitz 65, Volker Möbus 67,
Volkmar Müller 68, Ute Nöthlings 69, Marcus Schmidt 70, Rita Schmutzler 71, Andreas Schneeweiss 72, Florian Schütz 72,
Elmar Stickeler 73, Christoph Thomssen 74, Michael Untch 75, Simone Wesselmann 76, Arno Bücker 77, Andreas Buck 78,
Stephanie Stangl 2
Affiliations
1 Universitätsfrauenklinik Würzburg, Universität Würzburg,
Würzburg, Germany
2 Institut für Klinische Epidemiologie und Biometrie (IKE‑B),
Universität Würzburg, Würzburg, Germany
3 AWMF-Institut für Medizinisches Wissensmanagement,
Marburg, Germany
4 Klinik für Strahlentherapie und Radioonkologie,
Universitätsklinikum Düsseldorf, Düsseldorf, Germany
5 Office des Leitlinienprogrammes Onkologie, Berlin,
Germany
6 Universitätsfrauenklinik Ulm, Ulm, Germany
7 Frauenklinik, Klinikum Esslingen, Esslingen, Germany
8 Frauenklinik, Klinikum St. Marien Amberg, Amberg,
Germany
1056
9 Diagnostische Radiologie, Hamburg-Eimsbüttel, Germany
10 Praxis für Hämatologie und Onkologie, Kaiserslautern,
Germany
11 Tumorregister München, Institut für medizinische Informationsverarbeitung, Biometrie und Epidemiologie,
Ludwig-Maximilians-Universität München, München,
Germany
12 Universitätsfrauenklinik Düsseldorf, Düsseldorf, Germany
13 Stiftungsprofessur Selbsthilfeforschung, Tumorzentrum/
CCC Freiburg, Universitätsklinikum Freiburg, Freiburg,
Germany
14 Innere Klinik (Tumorforschung), Westdeutsches Tumorzentrum, Universitätsklinikum Essen, Essen, Germany
Wöckel A et al. Interdisciplinary Screening, Diagnosis, …
Geburtsh Frauenheilk 2018; 78: 1056–1088
15 Martin-Luther-Universität Halle-Wittenberg, Halle,
Germany
16 Klinik für Strahlentherapie und Radioonkologie,
Vivantes Klinikum, Neukölln Berlin, Germany
17 Berufsverband der Frauenärzte, Steinbach, Germany
18 BRCA-Netzwerk, Bonn, Germany
19 Institut für Pathologie, Medizinische Hochschule
Hannover, Hannover, Germany
20 Klinik für Allgemein-, Viszeral- und Kinderchirurgie,
Universitätsklinikum Düsseldorf, Düsseldorf, Germany
21 AGAPLESION Bethesda Klinik, Geriatrie der Universität
Ulm, Ulm, Germany
22 Universitätsfrauenklinik Tübingen, Tübingen, Germany
23 Medizinische Klinik mit Schwerpunkt Hämatologie,
Onkologie und Tumorimmunologie, Campus Benjamin
Franklin, Universitätsklinikum Charité, Berlin, Germany
24 Institut für Humangenetik, Universitätsklinikum HamburgEppendorf, Hamburg, Germany
25 III. Medizinische Klinik und Poliklinik, uct, Interdisziplinäre
Abteilung für Palliativmedizin, Universitätsmedizin
der Johannes Gutenberg Universität, Mainz, Germany
26 Institut für Pathologie, Universitätsklinikum HamburgEppendorf, Hamburg, Germany
27 Brustzentrum, Martin-Luther-Krankenhaus, Berlin,
Germany
28 Klinik für Strahlentherapie und Radioonkologie, Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany
29 Klinik für Tumorbiologie an der Universität Freiburg,
Freiburg, Germany
30 Radiologisches Institut, Universitätsklinikum Erlangen,
Erlangen, Germany
31 Frauenklinik Nathanstift, Klinikum Fürth, Fürth, Germany
32 Klinik für Radiologie und Nuklearmedizin, Klinikum
Frankfurt Höchst, Frankfurt, Germany
33 Physiotherapie, Hannover, Germany
34 Frauenselbsthilfe nach Krebs – Bundesverband e. V., Bonn,
Germany
35 Institut für Sozialmedizin und Epidemiologie, Universitätsklinikum Schleswig-Holstein, Lübeck, Germany
36 Ästhetisch plastische und rekonstruktive Chirurgie,
Camparihaus München, München, Germany
37 Gynäkologie und Geburtshilfe, Zuger Kantonsspital, Baar,
Switzerland
38 Konferenz Onkologischer Kranken- und Kinderkrankenpflege, Hamburg, Germany
39 Universitätsfrauenklinik, Abteilung für Gynäkologie,
Medizinische Universität Graz, Graz, Austria
40 Klinik für Frauenheilkunde und Geburtshilfe, Medizinische
Hochschule Hannover, Hannover, Germany
41 Klinik für Strahlentherapie und Radioonkologie,
Universitätsklinikum Mannheim, Mannheim, Germany
42 Klinik Reinhardshöhe Bad Wildungen, Bad Wildungen,
Germany
43 Praxis für interdisziplinäre Onkologie & Hämatologie,
Freiburg, Germany
44 Arbeitskreis Frauengesundheit, Berlin, Germany
Wöckel A et al. Interdisciplinary Screening, Diagnosis, …
45 Klinik für Radioonkologie und Strahlentherapie, Charité –
Universitätsmedizin Berlin, Berlin, Germany
46 Institut für Pathologie, Charité – Universitätsmedizin Berlin, Berlin, Germany
47 Universitätsfrauenklinik am Klinikum Südstadt, Rostock,
Germany
48 Centrum für Hämatologie und Onkologie Bethanien,
Frankfurt, Germany
49 Hospiz am Evangelischen Krankenhaus Düsseldorf,
Düsseldorf, Germany
50 Pathologisches Institut, Universität Heidelberg,
Heidelberg, Germany
51 Klinik für Strahlentherapie, Universitätsklinikum
Schleswig-Holstein, Kiel, Germany
52 Frauenklinik Offenburg, Ortenau Klinikum OffenburgGengenbach, Offenburg, Germany
53 Klinik für Radiologie, Charité – Universitätsmedizin Berlin,
Berlin, Germany
54 Deutscher Verband für Physiotherapie, Referat Bildung
und Wissenschaft, Köln, Germany
55 Frauenselbsthilfe nach Krebs, Wolfsburg, Germany
56 Centrum für Integrierte Onkologie Köln, Uniklinik Köln,
Köln, Germany
57 Frauenklinik, Universitätsklinikum Erlangen, CCC ErlangenEMN, Friedrich-Alexander-Universität Erlangen-Nürnberg,
Erlangen, Germany
58 Klinik für Gynäkologie incl. Brustzentrum, Charité –
Universitätsmedizin Berlin, Berlin, Germany
59 Brustzentrum, Frauenklinik, Universität München (LMU),
München, Germany
60 Klinik für Gynäkologie und Geburtshilfe, Krankenhaus
Nordwest, Frankfurt, Germany
61 Lehrstuhl für Ernährungsmedizin, Klinikum rechts der Isar,
Technische Universität München, München, Germany
62 Referenzzentrum Mammographie München, München,
Germany
63 Klinik für Innere Medizin II, Universitätsklinikum Jena, Jena,
Germany
64 Klinik für Gynäkologie und Geburtshilfe, Sana Klinikum
Offenbach, Offenbach, Germany
65 German Breast Group, Neu-Isenburg, Germany
66 Gynäkologisch-onkologische Praxis, Hannover, Germany
67 Klinik für Gynäkologie und Geburtshilfe, Klinikum
Frankfurt Höchst, Frankfurt, Germany
68 Klinik und Poliklinik für Gynäkologie, Universitätsklinikum
Hamburg-Eppendorf, Hamburg, Germany
69 Institut für Ernährungs- und Lebensmittelwissenschaften,
Rheinische Friedrich-Wilhelms Universität Bonn, Bonn,
Germany
70 Klinik und Poliklinik für Geburtshilfe und Frauengesundheit, Universitätsmedizin der Johannes GutenbergUniversität Mai, Germany nz, Mainz
71 Zentrum Familiärer Brust- und Eierstockkrebs,
Universitätsklinikum Köln, Köln, Germany
72 Nationales Centrum für Tumorerkrankungen,
Universitätsklinikum Heidelberg, Heidelberg, Germany
Geburtsh Frauenheilk 2018; 78: 1056–1088
1057
GebFra Science | Guideline
73 Klinik für Gynäkologie und Geburtsmedizin, Uniklinik
RWTH Aachen, Aachen, Germany
74 Universitätsfrauenklinik Halle (Saale), Halle (Saale),
Germany
75 Klinik für Geburtshilfe und Gynäkologie, Helios Klinikum
Berlin-Buch, Berlin, Germany
76 Deutsche Krebsgesellschaft, Berlin, Germany
77 Klinik für Diagnostische und Interventionelle Radiologie
am UKS, Universität des Saarlandes, Homburg, Germany
78 Nuklearmedizinische Klinik und Poliklinik des Universitätsklinikums Würzburg, Würzburg, Germany
Key words
breast cancer, guideline, therapy, primary breast cancer,
metastatic breast cancer
Schlüsselwörter
Brustkrebs, Leitlinie, Therapie, primäres Mammakarzinom,
metastasiertes Mammakarzinom
guidelines. They were combined with reviews of evidence
compiled using PICO (Patients/Interventions/Control/Outcome) questions and with the results of a systematic search
of literature databases followed by the selection and evaluation of the identified literature. The interdisciplinary working
groups took the identified materials as their starting point
and used them to develop suggestions for recommendations
and statements, which were then modified and graded in a
structured consensus process procedure.
Recommendations Part 2 of this short version of the guideline presents recommendations for the therapy of primary, recurrent and metastatic breast cancer. Loco-regional therapies
are de-escalated in the current guideline. In addition to reducing the safety margins for surgical procedures, the guideline
also recommends reducing the radicality of axillary surgery.
The choice and extent of systemic therapy depends on the respective tumor biology. New substances are becoming available, particularly to treat metastatic breast cancer.
ZU SAM ME N FA SS UN G
received
accepted
19. 6. 2018
20. 6. 2018
Ziele Das Ziel dieser offiziellen Leitlinie, die von der Deut-
Bibliography
DOI https://doi.org/10.1055/a-0646-4630
Geburtsh Frauenheilk 2018; 78: 1056–1088 © Georg Thieme
Verlag KG Stuttgart · New York | ISSN 0016‑5751
Correspondence
Prof. Dr. med. Achim Wöckel
Frauenklinik und Poliklinik, Universitätsklinikum Würzburg
Josef-Schneider-Straße 4, 97080 Würzburg, Germany
woeckel_a@ukw.de
Deutsche Version unter:
https://doi.org/10.1055/a-0646-4630
AB STR AC T
Purpose The aim of this official guideline coordinated and
published by the German Society for Gynecology and Obstetrics (DGGG) and the German Cancer Society (DKG) was to optimize the screening, diagnosis, therapy and follow-up care of
breast cancer.
Method The process of updating the S3 guideline published
in 2012 was based on the adaptation of identified source
I
Citation format
Guideline Information
Guidelines program of the DGGG, OEGGG and SGGG
Information on the guidelines program is available at the end of
the guideline.
1058
schen Gesellschaft für Gynäkologie und Geburtshilfe (DGGG)
und der Deutschen Krebsgesellschaft (DKG) publiziert und koordiniert wurde, ist es, die Früherkennung, Diagnostik, Therapie und Nachsorge des Mammakarzinoms zu optimieren.
Methode Der Aktualisierungsprozess der S3-Leitlinie aus 2012
basierte zum einen auf der Adaptation identifizierter Quellleitlinien und zum anderen auf Evidenzübersichten, die nach Entwicklung von PICO-Fragen (PICO: Patients/Interventions/Control/Outcome), systematischer Recherche in Literaturdatenbanken sowie Selektion und Bewertung der gefundenen Literatur angefertigt wurden. In den interdisziplinären Arbeitsgruppen wurden auf dieser Grundlage Vorschläge für Empfehlungen – und Statements erarbeitet, die im Rahmen von strukturierten Konsensusverfahren modifiziert und graduiert wurden.
Empfehlungen Teil 2 dieser Kurzversion der Leitlinie zeigt
Empfehlungen zur Therapie des primären, rezidivierten und
metastasierten Mammakarzinoms: Die lokoregionären Therapien erfahren in der aktuellen Leitlinie eine Deeskalation. Neben einer Verringerung des Sicherheitsabstandes bei den operativen Verfahren gibt die Leitlinie auch Empfehlungen zu
einer reduzierten Radikalität bei axillären Interventionen. Die
Systemtherapie richtet sich nach den tumorbiologischen Eigenschaften, neue Substanzen stehen insbesondere beim
metastatierten Mammakarzinom zur Verfügung.
Interdisciplinary Screening, Diagnosis, Therapy and Follow-up of
Breast Cancer. Guideline of the DGGG and the DKG (S3-Level, AWMF
Registry Number 032/045OL, December 2017) – Part 2 with Recommendations for the Therapy of Primary, Recurrent and Advanced
Breast Cancer. Geburtsh Frauenheilk 2018; 78: 1056–1088
Wöckel A et al. Interdisciplinary Screening, Diagnosis, …
Geburtsh Frauenheilk 2018; 78: 1056–1088
Guideline documents
The complete long version together with a summary of the conflicts of interest of all the authors and a short version of the guideline are available in German on the AWMF homepage under:
http://www.awmf.org/leitlinien/detail/ll/032-045OL.html or
www.leitlinienprogramm-onkologie.de
Guideline authors
The German Society for Gynecology and Obstetrics (DGGG),
working together with the German Cancer Society (DKG), was
the lead professional organization behind this guideline. The updated guideline presented here was supported by German Cancer
Aid in the context of their oncology guidelines program (OL program). The working groups for this guideline consisted of members of the guideline steering group (▶ Table 1), specialists nominated by participating professional societies and organizations
(▶ Table 2), and experts invited to participate by the steering
committee (▶ Table 3), and they are the authors of this guideline.
Only mandate holders nominated by participating professional
societies and organizations were eligible to vote on a chapter-bychapter basis during the voting process (consensus process) after
they had disclosed and excluded any conflicts of interest. The
guideline was compiled with the direct participation of four patient representatives.
▶ Table 1 Steering committee.
Name
City
1
Prof. Dr. Ute-Susann Albert
Marburg
2
Prof. Dr. Wilfried Budach
Düsseldorf
3
Dr. Markus Follmann, MPH, MSc
Berlin
4
Prof. Dr. Wolfgang Janni
Ulm
5
Prof. Dr. Ina Kopp
Marburg
6
Prof. Dr. Rolf Kreienberg
Landshut
7
PD Dr. Mathias Krockenberger
Würzburg
8
Prof. Dr. Thorsten Kühn
Esslingen
9
Dipl.-Soz. Wiss. Thomas Langer
Berlin
10
Dr. Monika Nothacker
Marburg
11
Prof. Dr. Anton Scharl
Amberg
12
Prof. Dr. Ingrid Schreer
Hamburg-Eimsbüttel
13
Prof. Dr. Achim Wöckel
(Leitlinienkoordination)
Würzburg
Methodological consulting: Prof. Dr. P. U. Heuschmann,
University of Würzburg
▶ Table 2 Participating professional societies and organizations.
Professional societies
1st mandate holder
2nd mandate holder (deputy)
Radiological Oncology Working Group
[AG Radiologische Onkologie (ARO)]
Prof. Dr. Wilfried Budach, Düsseldorf
Prof. Dr. Frederik Wenz, Mannheim
Supportive Measures in Oncology, Rehabilitation and Social Medicine
Working Group [AG Supportive Maßnahmen in der Onkologie,
Rehabilitation und Sozialmedizin (ASORS)]
Prof. Dr. Hartmut Link, Kaiserslautern
Prof. Dr. Oliver Rick, Bad Wildungen
Association of German Tumor Centers
[Arbeitsgemeinschaft Deutscher Tumorzentren e. V. (ADT)]
Prof. Dr. Jutta Engel, Munich
Prof. Dr. Dieter Hölzel, Munich
German Society of Gynecological Oncology
[Arbeitsgemeinschaft für gynäkologische Onkologie (AGO)]
Prof. Dr. Tanja Fehm, Düsseldorf
Prof. Dr. Anton Scharl, Amberg
Prevention and Integrative Oncology Working Group
[AG Prävention und Integrative Onkologie (PRiO)]
Prof. Dr. Volker Hanf, Fürth
Prof. Dr. Karsten Münstedt, Offenburg
Psycho-oncology Working Group of the German Cancer Society
[Arbeitsgemeinschaft für Psychoonkologie in der Deutschen
Krebsgesellschaft e. V. (PSO)]
Prof. Dr. Joachim Weis, Freiburg
Internal Oncology Working Group
[Arbeitsgemeinschaft Internistische Onkologie (AIO)]
Dr. Anja Welt, Essen
Dr. Matthias Zaiss, Freiburg
Womenʼs Health Work Group
[Arbeitskreis Frauengesundheit (AKF)]
Prof. Dr. Anke Steckelberg, Halle
Gudrun Kemper, Berlin
Professional Association of German Radiation Therapists
[Berufsverband Deutscher Strahlentherapeuten e. V. (BVDST)]
Prof. Dr. Petra Feyer, Berlin
Prof. Dr. Volker Budach, Berlin
Professional Association of German Gynecologists
[Berufsverband für Frauenärzte e. V.]
Dr. Klaus König, Steinbach
BRCA Network [BRCA-Netzwerk e. V.]
Andrea Hahne, Bonn
Traudl Baumgartner, Bonn
German Society for Pathology
[Deutsche Gesellschaft für Pathologie]
Prof. Dr. Hans H. Kreipe, Hanover
Prof. Dr. Carsten Denkert, Berlin
Continued next page
Wöckel A et al. Interdisciplinary Screening, Diagnosis, …
Geburtsh Frauenheilk 2018; 78: 1056–1088
1059
GebFra Science | Guideline
▶ Table 2 Participating professional societies and organizations.
(continued)
Professional societies
1st mandate holder
2nd mandate holder (deputy)
Surgical Oncology Working Group
[Chirurgische AG für Onkologie (CAO‑V)]
Prof. Dr. Wolfram Trudo Knoefel,
Düsseldorf
German Society of Geriatrics
[Deutsche Gesellschaft für Geriatrie (DGG)]
Prof. Dr. Michael Denkinger, Ulm
German Society of Gynecology and Obstetrics
[Deutsche Gesellschaft für Gynäkologie und Geburtshilfe (DGGG)]
Prof. Dr. Sara Brucker, Tübingen
Prof. Dr. Bernd Gerber, Rostock
German Society of Hematology and Oncology
[Deutsche Gesellschaft für Hämatologie und Onkologie (DGHO)]
Prof. Dr. Diana Lüftner, Berlin
Prof. Dr. Hans Tesch, Frankfurt
German Society of Nuclear Medicine
[Deutsche Gesellschaft für Nuklearmedizin (DGN)]
Prof. Dr. Andreas Buck
German Society of Human Genetics
[Deutsche Gesellschaft für Humangenetik e. V. (GfH)]
Prof. Dr. Christian Kubisch, Hamburg
German Society for Palliative Medicine
[Deutsche Gesellschaft für Palliativmedizin (DGP)]
Dr. Christina Gerlach, MSc, Mainz
Dr. Susanne Hirsmüller, MSc,
Düsseldorf
Professional Association of German Pathologists
[Bundesverband Deutscher Pathologen e. V.]
Prof. Dr. Annette Lebeau, Hamburg
Prof. Dr. Hans-Peter Sinn, Heidelberg
German Society of Psychosomatic Obstetrics and Gynecology
[Deutsche Gesellschaft für psychosomatische Frauenheilkunde
und Geburtshilfe (DGPFG)]
PD Dr. Friederike Siedentopf, Berlin
German Society for Radiation Oncology
[Deutsche Gesellschaft für Radioonkologie (DEGRO)]
Prof. Dr. Cordula Petersen, Hamburg
German Society for Rehabilitation Sciences
[Deutsche Gesellschaft für Rehabilitationswissenschaften (DGRW)]
Prof. Dr. Hans Helge Bartsch, Freiburg
German Society for Senology
[Deutsche Gesellschaft für Senologie (DGS)]
Prof. Dr. Rüdiger Schulz-Wendtland,
Erlangen
German Society for Ultrasound in Medicine
[Deutsche Gesellschaft für Ultraschall in der Medizin e. V. (DEGUM)]
Prof. Dr. Markus Hahn, Tübingen
German Roentgen Society
[Deutsche Röntgengesellschaft e. V.]
Prof. Dr. Markus Müller-Schimpfle,
Frankfurt
Prof. Dr. Jürgen Dunst, Kiel
Till 31.12.16: Prof. Dr. Ulrich Bick,
Berlin
from 01.01.17: PD Dr. E. Fallenberg,
Berlin
German Physiotherapy Society
[Deutscher Verband für Physiotherapie e. V. (ZVK)]
Ulla Henscher, Hanover
Reina Tholen, Cologne
Self-help group for women after cancer [Frauenselbsthilfe nach Krebs]
Dr. Renza Roncarati, Bonn
Roswita Hung, Wolfsburg
Association of Epidemiological Cancer Registries in Germany
[Gesellschaft der epidemiologischen Krebsregister in Deutschland e. V.
(GEKID)]
Prof. Dr. Alexander Katalinic, Lübeck
German Society of Plastic, Reconstructive and Aesthetic Surgery
[Gesellschaft der Plastischen, Rekonstruktiven und Ästhetischen
Chirurgie (DGPRÄC)]
Prof. Dr. Christoph Heitmann, Munich
Swiss Society of Gynecology and Obstetrics
[Gynécologie Suisse (SGGG)]
Dr. Christoph Honegger, Baar
Conference of Oncological Nursing and Pediatric Nursing
[Konferenz Onkologischer Kranken- und Kinderkrankenpflege (KOK)]
Kerstin Paradies, Hamburg
Austrian Society of Gynecology and Obstetrics
[Österreichische Gesellschaft für Gynäkologie und Geburtshilfe
(OEGGG)]
Prof. Dr. Vesna Bjelic-Radisic, Graz
Ultrasound Diagnosis in Gynecology and Obstetrics
[Ultraschalldiagnostik in Gynäkologie und Geburtshilfe (ARGUS)]
Prof. Dr. med. Dr. h. c. Friedrich
Degenhardt, Hanover
1060
Wöckel A et al. Interdisciplinary Screening, Diagnosis, …
Geburtsh Frauenheilk 2018; 78: 1056–1088
Abbreviations of the S3 Breast Cancer Guideline
▶ Table 3 Experts contributing in an advisory capacity and other contributors.
Name
City
Experts contributing in an advisory capacity
PD Dr. Freerk Baumann
Cologne
Prof. Dr. Matthias W. Beckmann
Erlangen
Prof. Dr. Jens Blohmer
Berlin
Prof. Dr. Peter Fasching
Erlangen
Prof. Dr. Nadia Harbeck
Munich
Prof. Dr. Peyman Hadji
Frankfurt
Prof. Dr. Hans Hauner
Munich
Prof. Dr. Sylvia Heywang-Köbrunner
Munich
Prof. Dr. Jens Huober
Ulm
Prof. Dr. Jutta Hübner
Jena
Prof. Dr. Christian Jackisch
Offenbach
Prof. Dr. Sibylle Loibl
Neu-Isenburg
Prof. Dr. Hans-Jürgen Lück
Hanover
Prof. Dr. Michael P. Lux
Erlangen
Prof. Dr. Gunter von Minckwitz
Neu-Isenburg
Prof. Dr. Volker Möbus
Frankfurt
Prof. Dr. Volkmar Müller
Hamburg
Prof. Dr. Ute Nöthlings
Kiel
Prof. Dr. Marcus Schmidt
Mainz
Prof. Dr. Rita Schmutzler
Cologne
Prof. Dr. Andreas Schneeweiss
Heidelberg
Prof. Dr. Florian Schütz
Heidelberg
Prof. Dr. Elmar Stickeler
Aachen
Prof. Dr. Christoph Thomssen
Halle (Saale)
Prof. Dr. Michael Untch
Berlin
Dr. Simone Wesselmann, MBA
Berlin
Dr. Barbara Zimmer, MPH, MA (Oncology Competence Center, MDK [Medical Service of the Health
Insurance Funds] North-Rhine, not listed as an
author at the explicit request of the MDK)
Düsseldorf
Other contributors
Katharina Brust, BSc (guideline secretariat)
Würzburg
Dr. Jasmin Festl (guideline assessment,
selection of relevant publications)
Würzburg
Steffi Hillmann, MPH
(search for and assessment of guidelines)
Würzburg
PD Dr. Mathias Krockenberger
(selection of relevant publications)
Würzburg
Stephanie Stangl, MPH
Würzburg
Dr. Tanja Stüber
(selection of relevant publications)
Würzburg
Wöckel A et al. Interdisciplinary Screening, Diagnosis, …
ADH
AI
AML
APBI
ASCO
ADL
AUC
BÄK
BCT
BI-RADS
BMI
BPM
BPSO
BRCA1/2
CAM
CAP
CD
CDLT
CGA
CHF
CIPN
CISH
CM
CNB
CNS
CT
DCIS
DBT
DFS
DGS
DKG
DMP
EC
ECE
EIC
ER
ESA
ESAS
ET
FEA
FISH
FN
FNA
FNB
G‑CSF
GnRHa
HADS
HER2
HT
IARC
IBC
IHC
IMRT
IORT
Geburtsh Frauenheilk 2018; 78: 1056–1088
atypical (intra) ductal hyperplasia
aromatase inhibitor
acute myeloid leukemia
accelerated partial breast irradiation
American Society of Clinical Oncology
activities of daily living
area under the curve
German Medical Association (Bundesärztekammer)
breast-conserving therapy
breast imaging reporting and data system
body mass index
bilateral prophylactic mastectomy
bilateral prophylactic salpingo-oophorectomy
breast cancer-associated gene 1/2
complementary and alternative methods
College of American Pathologists
cognitive dysfunction
complex/complete decongestive lymphatic therapy
comprehensive geriatric assessment
chronic heart failure
chemotherapy-induced peripheral neuropathy
chromogenic in situ hybridization
contrast media
core needle biopsy
central nervous system
computed tomography
ductal carcinoma in situ
digital breast tomosynthesis
disease-free survival
German Society for Senology
(Deutsche Gesellschaft für Senologie)
German Cancer Society
disease management program
expert consensus
extracapsular tumor extension
extensive intraductal component
estrogen receptor
erythropoiesis-stimulating agents
Edmonton Symptom Assessment Scale
estrogen therapy
flat epithelial atypia
fluorescent in situ hybridization
febrile neutropenia
fine needle aspiration
fine needle biopsy
granulocyte colony-stimulating factor
gonadotropin-releasing hormone agonist
Hospital Anxiety and Depression Scale
human epidermal growth factor receptor 2
hormone therapy
International Agency for Research on Cancer
inflammatory breast cancer
immunohistochemistry
intensity-modulated radiotherapy
intraoperative radiation therapy
1061
GebFra Science | Guideline
IQWIG
Institute for Quality and Efficiency in Healthcare
(Institut für Qualität und Wirtschaftlichkeit
im Gesundheitswesen)
ISH
in situ hybridization
ITC
intrathecal chemotherapy
LABC
locally advanced breast cancer
LCIS
lobular carcinoma in situ
LN
lymph node
LoE
level of evidence
L-spine
lumbar spine
LVEF
left ventricular ejection fraction
LVI
lymphatic vessel invasion
MDS
myelodysplastic syndrome
MG
mammography
MRI
magnetic resonance imaging
MSP
mammography screening program
NAC
nipple-areolar complex
NACT
neoadjuvant chemotherapy
NCCN
National Comprehensive Cancer Network
NICE
National Institute for Health and Clinical Excellence
NNT
number needed to treat
NZGG
New Zealand Guidelines Group
OP
operation
OS
overall survival
PBI
partial breast irradiation
pCR
pathological complete remission
PET
positron emission tomography
PFS
progression-free survival
PI
proliferation index
PMRT
postoperative radiotherapy
PNP
polyneuropathy
POS
Palliative Outcome Scale
PR
progesterone receptor
PST
primary systemic therapy
QoL
quality of life
RCT
randomized controlled trial
RFA
radiofrequency ablation
ROR
risk of recurrence
RR
relative risk
RS
recurrence score
SABCS
San Antonio Breast Cancer Symposium
SBRT
stereotactic radiotherapy
SGB
German Social Security Code (Sozialgesetzbuch)
SIB
simultaneous integrated boost
SIGN
Scottish Intercollegiate Guidelines Network
SISH
silver-enhanced in situ hybridization
SLN
sentinel lymph node
SLNB
sentinel lymph node biopsy
SLNE
sentinel lymph node excision
s/p
status post
SSM
skin-sparing mastectomy
TACE
transarterial chemoembolization
TILs
tumor-infiltrating lymphocytes
TNBC
triple-negative breast cancer
TNM classification
tumor–node–metastasis classification
T-spine
thoracic spine
1062
UICC
US
VMAT
WHO
II
Union for International Cancer Control
ultrasound
volumetric arc therapy
World Health Organization
Guideline Application
Purpose and objectives
The most important reason to update this interdisciplinary guideline was the epidemiological impact of breast cancer and its associated burden of disease, both of which are still high. This is the
context in which the impact of new management concepts and
their implementation needed to be evaluated.
Targeted areas of patient care
The guideline covers outpatient, inpatient and rehabilitative care.
Target patient groups
The recommendations of the guideline are aimed at all women
and men who develop breast cancer as well as their relatives.
Target user groups/Target audience
The recommendations of the guideline are addressed to all physicians and professionals who provide screening services for women
or care for patients with breast cancer (gynecologists, general
practitioners, human geneticists, radiologists, pathologists, radio-oncologists, hemato-oncologists, psycho-oncologists, physiotherapists, nursing staff, etc.).
Adoption of the guideline and period of validity
This guideline is valid from December 1, 2017 through to November 30, 2022. Because of the contents of this guideline, this period of validity is only an estimate. It may become necessary to update the guideline because of new scientific evidence and knowledge as well as new developments affecting the methodology
used for these guidelines. It is also necessary to edit and revise
the guidelineʼs contents and re-evaluate and revise the key statements and recommendations of the guidelines at regular intervals.
III
Methodology
Basic principles
The method used to prepare this guideline was determined by the
class to which this guideline was assigned. The AWMF Guidance
Manual (version 1.0) has set out the respective rules and regulations for the different classes of guidelines. Guidelines are differentiated into lowest (S1), intermediate (S2) and highest class (S3).
The lowest class is defined as a set of recommendations for action
compiled by a non-representative group of experts. In 2004, the
S2 class was subdivided into two subclasses: a systematic evidence-based subclass (S2e) and a structural consensus-based
subclass (S2k). The highest class (S3) combines both approaches.
This guideline is classified as: S3.
Wöckel A et al. Interdisciplinary Screening, Diagnosis, …
Geburtsh Frauenheilk 2018; 78: 1056–1088
Grading of evidence
This guideline used the 2009 version of the system of the Oxford
Centre for Evidence-based Medicine (levels 1–5) to classify the risk
of bias in identified studies. This system classifies studies according to various clinical questions (benefit of therapy, prognostic
value, diagnostic validity). For more detailed information, abbreviations and notes, see: https://www.cebm.net/2009/06/oxfordcentre-evidence-based-medicine-levels-evidence-march-2009/
Grading of recommendations
While the classification of the quality of the evidence (strength of
evidence) serves as an indication of the robustness of the published data and therefore expresses the extent of certainty/uncertainty regarding the data, the classification of the level of recommendation reflects the results of weighing up the desirable and
adverse consequences of alternative approaches. This guideline
shows the level of evidence for the underlying studies as well as
the strength of the recommendation (level of recommendation)
for all evidence-based Statements and Recommendations. This
guideline differentiates between three levels of recommendation
(▶ Table 4). The levels reflect the strength of the respective recommendation and are also mirrored in the terms used to formulate the recommendation.
▶ Table 4 Grading of recommendations.
Level of recommendation
Description
Syntax
A
strong recommendation,
highly binding
must/
must not
B
recommendation,
moderately binding
should/
should not
0
open recommendation,
not binding
may/
may not
Statements
Statements are expositions or explanations of specific facts, circumstances or problems with no direct recommendations for action. Statements are adopted after a formal consensus process using the same approach as that used when formulating recommendations and can be based either on trial results or expert opinions.
Expert consensus
As the expression implies, this term refers to consensus decisions
taken specifically with regard to Recommendations/Statements
Wöckel A et al. Interdisciplinary Screening, Diagnosis, …
without a previous systematic search of the literature (S2k) or
when evidence is lacking (S2e/S3). The term “Expert Consensus”
(EC) used here is synonymous with terms such as “Good Clinical
Practice” (GCP) or “Clinical Consensus Point” used in other guidelines. The level of recommendation is graded as previously described in the Chapter “Grading of recommendations”, but the
grading is only presented semantically (“must”/“must not” or
“should”/“should not” or “may”/“may not”) without the use of
symbols.
Guideline report
To edit and update the various topic areas, an adaptation of existing guidelines was planned for around 80 % of Statements and
Recommendations in accordance with the AWMF Guidance Manual. To do this, a systematic search was carried out for source
guidelines developed specifically for women with breast cancer
and published after 2013. Findings were compared with the IQWiG guideline report No. 224 (Systematische Leitlinienrecherche
und -bewertung sowie Extraktion relevanter Recommendations
für das DMP Brustkrebs [Systematic guideline search and appraisal
as well as extraction of relevant recommendations for a breast
cancer DMP]). A further inclusion criterion was compliance with
methodological standards. Guidelines were included if they complied with at least 50 % of Domain 3 (Rigour of Development) of
the AGREE II instrument. A corresponding search and evidence assessment was specified in accordance with AWMF guidelines (systematic search, selection, compilation of evidence tables) for
those recommendations which could not be adapted or had to
be newly created. For newly developed Recommendations and
Statements, appropriate key questions were formulated and a systematic search was carried out using aggregated sources of evidence (meta-analyses, systematic reviews, etc.) as well as individual publications in specific cases. A suitable list of titles and abstracts up to and including the identification of the full text were
selected by two independent raters. After the search and selection processes were completed, the necessary evidence tables
which formed the basis for the consensus conferences were compiled by the Methods group (financial support was provided and
allowed a researcher to be specifically hired for this purpose).
The classification system of the Oxford Centre for Evidence-based
Medicine (version 2009) was used to grade the evidence. To update this guideline, Recommendations and Statements were
adopted and levels of recommendation (▶ Table 4) were determined during two structured consensus conferences which were
preceded by a preliminary online ballot.
The guideline report provides an overview of the search strategies and selection processes used to select the literature and to
formulate and grade the recommendations.
Geburtsh Frauenheilk 2018; 78: 1056–1088
1063
GebFra Science | Guideline
1.1.3
IV
Guideline
1
Treatment of primary breast cancer
1.1
1.1.1
Surgical treatment for invasive carcinoma
General recommendations
No.
Recommendations/
Statements
EG
LoE
Sources
4.19.
a) The basic therapy for all nonadvanced breast cancers is complete resection of the tumor
(R0 status).
A
1a
[1, 2]
b) The resection margin status
has a prognostic effect on invasive breast cancer. There is a significant association between resection margin status (positive
vs. negative) and local rate of
recurrence.
A
1a
[3]
1.1.2
No.
Recommendations/
Statements
EG
LoE
Sources
4.21.
a) Mastectomy must be performed if any of the following
indications are present:
A
2b
[11 – 13]
b) If the resection margins are
tumor-free, mastectomy may
also be performed as a skinsparing procedure with or without preservation of the NAC.
0
2a
[14 – 17]
c) Depending on the tumor location and tumor size, mastectomy
may be necessary in individual
cases, even if multiple cancers
are present.
0
2a
[18 – 25]
d) Contralateral prophylactic
mastectomy to reduce the risk
of contralateral breast cancer
should not be carried out in nonmutation carriers or patients
with no evidence of high familial
risk.
B
2b
[26 – 28]
▪ Incomplete removal of the
tumor (incl. any intraductal
component), even after secondary resection
▪ Inflammatory breast cancer
(generally even in cases with
pathological complete remission)
▪ When follow-up radiation
of the breast after breastconserving therapy is contraindicated but radiation is
absolutely indicated
▪ at the request of the patient
who has been fully informed
about her range of options
Breast-conserving therapy
Randomized clinical studies have shown that if certain clinical and
histological parameters are taken into account, breast-conserving
therapy achieves identical survival rates to those of mastectomy.
No.
Recommendations/
Statements
4.20.
a) The goal of surgical therapy is
complete removal of the tumor.
Breast-conserving therapy (BCT)
followed by full breast radiotherapy is equivalent to mastectomy
alone in terms of survival rates.
b) All appropriate patients,
whether or not they have previously had primary systemic therapy, must be informed about the
possibility of breast-conserving
therapy (BCT) and about mastectomy with the options of primary or secondary reconstruction.
1064
EG
LoE
Sources
1a
[4 – 10]
Mastectomy
EC
1.1.4
Reconstructive plastic surgery procedures
No.
Recommendations/
Statements
EG
LoE
Sources
4.22.
Every patient scheduled for mastectomy must be informed about
the options of having immediate
or subsequent breast reconstruction or the option of forgoing reconstructive procedures; these patients should be
offered the opportunity to contact other similarly affected
people and self-help groups or
organizations.
A
2b
[16, 29,
30]
Wöckel A et al. Interdisciplinary Screening, Diagnosis, …
Geburtsh Frauenheilk 2018; 78: 1056–1088
1.1.5
Axillary surgery
No.
Recommendations/Statements
EG
4.23.
a) Axillary staging is an essential part of the surgical therapy of invasive breast cancer.
EC
b) Staging must include sentinel lymph node biopsy (SLNB) even if the lymph node status is unremarkable
on palpation and ultrasound.
1.2
No.
4.36.
LoE
Sources
A
1a
[30 – 32]
c) Clinically significant lymph nodes that are negative on biopsy should also be resected during SLNB.
B
2b
[30, 33]
d) Patients with pT1–pT2/cN0 tumors who undergo breast-conserving surgery followed by percutaneous radiation by tangential opposing fields (tangential radiation therapy) and who have one or two positive sentinel lymph
nodes should not undergo axillary dissection.
B
1b
[31]
e) Patients who have mastectomy or to whom the above-listed criteria do not apply should undergo axillary
dissection or receive axillary radiotherapy.
B
1b
[31, 34]
f) Targeted therapy of the lymph drainage areas (surgery, radiotherapy) must not be carried out if the patient
only has micro-metastasis.
B
1b
[35, 36]
g) Patients treated with primary systemic therapy (PST) and whose lymph node status on palpation and
ultrasound is negative prior to treatment should have SLN after PST.
B
2b
[37, 38]
h) Patients treated with primary systemic therapy (PST) whose nodal status on punch biopsy is positive (cN1)
prior to treatment but whose nodal status after PST is clinically negative (ycN0) should undergo axillary
dissection.
B
2b
[38, 39]
i) Patients treated with primary systemic therapy (PST) who have a positive nodal status before and after PST
must undergo axillary dissection.
EC
j) Patients must not undergo axillary staging if there is evidence of distant metastasis.
EC
Adjuvant radiation therapy for breast cancer
Recommendations/Statements
EG
LoE
Sources
After breast-conserving surgery for invasive carcinoma the affected breast must be treated with radiotherapy.
A
1a
[40 – 47]
Provided the resection margins were tumor-free, patients with a clearly limited life expectancy (< 10 years) and
a small (pT1), node-negative (pN0), hormone receptor-positive HER2-negative tumor and endocrine adjuvant
therapy may avoid radiation therapy and accept the increased risk of local recurrence after receiving individual
counselling.
Note for all Recommendations: all single positions are OR conjunctions. AND conjunctions are represented by “and”.
4.37.
Radiotherapy of the breast should be administered in hypofractionated doses (total dose: approx. 40 Gy in
approx. 15–16 fractions over approx. 3 to 5 weeks) or may be administered as a standard fractionated regimen
(total dose: approx. 50 Gy in approx. 25–28 fractions over approx. 5–6 weeks).
B/0
1a
[48 – 54]
4.38.
Local dose escalation (boost radiotherapy) of the tumor bed reduces the local rate of recurrence in the breast
without achieving a significant survival benefit.
A/B
1a
[55 – 58]
Boost radiotherapy
▪ must therefore be carried out in all patients aged ≤ 50 years and
▪ should only be carried out in patients aged > 51 years if they have an increased risk of local recurrence
(G3, HER2-positive, triple-negative, >T1).
4.39.
Partial breast irradiation alone (as an alternative to secondary whole breast irradiation) may be carried out
in patients with a low risk of recurrence.
0
1a
[59 – 64]
4.40.
Postoperative radiotherapy of the thoracic wall after mastectomy reduces the risk of loco-regional recurrence
and improves the survival of patients with locally advanced, node-positive breast cancer.
A
1a
[65]
4.41.
Radiation of the thoracic wall after mastectomy is indicated in the following situations:
A
1a
[65 – 79]
▪ pT4
▪ pT3 pN0 R0 when additional risk factors are present (lymph node invasion (L1), G3 grading, premenopausal,
age < 50 years)
▪ R1/R2 resection and no possibility of a second curative resection
a) Post-mastectomy radiation must be carried out as a standard procedure if more than 3 axillary lymph nodes
are affected.
b) If 1–3 axillary lymph nodes show tumor involvement, post-mastectomy radiation must be carried out if the
patient has an increased risk of recurrence (e.g. HER2-positive, triple-negative, G3, L1, Ki-67 > 30 %, > 25 % of
excised lymph nodes show tumor involvement; age ≤ 45 years with additional risk factors such as medial tumor
location or tumor size > 2 cm, or ER-negative).
c) PMRT should not be carried out if 1–3 axillary lymph nodes show tumor involvement and the tumor has
a low risk of local recurrence (pT1, G1, ER-positive, HER2-negative, at least 3 characteristics must apply).
d) For all other patients with 1–3 axillary lymph nodes with tumor involvement, the individual indication for
treatment must be decided on by an interdisciplinary board.
Wöckel A et al. Interdisciplinary Screening, Diagnosis, …
Geburtsh Frauenheilk 2018; 78: 1056–1088
1065
GebFra Science | Guideline
No.
Recommendations/Statements
EG
LoE
Sources
4.42.
After primary (neoadjuvant) systemic therapy, the indication for post-mastectomy radiotherapy must be based
on the clinical staging prior to treatment; for pCR (ypT0 and ypN0) the indication for treatment must be decided
on by an interdisciplinary tumor board and depends on the patientʼs individual risk profile.
A
1a
[80 – 83]
Pretreatment
Post-treatment
RT‑BCT1
PMRT2
RT‑LAW3
locally advanced
pCR/no pCR
yes
Yes
yes
cT1/2 cN1+
ypT1+ o. ypN1+ (no pCR)
yes
yes
yes
cT1/2 cN1+
ypT0/is ypN0 (SLNE ≥ 3 LN)
yes
cases with high risk4
cT1/2 cN0 (US obligatory)
ypT0/is ypN0 (SLNE ≥ 3 LN)
yes
no
1
with standard tangential treatment
2
if the patient underwent a mastectomy
3
together with PMRT or RT because of BCT
4
Criteria for a high risk of recurrence:
no
pN0 premenopausal, high risk: central or medial location, and (G2–3 and ER/PgR-negative)
pN1a high risk: central or medial location and (G2–3 or ER/PgR-negative) or premenopausal, lateral location and (G2–3 or ER/PgR-negative)
No.
Recommendations/Statements
EG
LoE
Sources
4.43.
Adjuvant irradiation of regional lymph drainage areas improves disease-free survival and overall survival rates in
a subgroup of patients.
1a
[84 – 88]
4.44.
a) Irradiation of the supra-/infraclavicular lymph nodes may be an option for patients with pN0 or pN1mi stage
disease under the following circumstances if all of the following conditions are met:
0
2a/2b
[84 – 90]
B
2a
[84 – 90]
c) Irradiation of the supra-/infraclavicular lymph nodes must be generally carried out in all patients with
> 3 affected axillary lymph nodes.
A
2a
[84 – 90]
a) Irradiation of the internal thoracic artery lymph nodes may be carried out in patients without or with minimal
axillary involvement (pN0 or pN1mi) in the following circumstances:
0
2b
[84 – 88]
B
2b
[84 – 88]
B
2b
[84 – 88]
d) If tumor involvement of the internal thoracic artery lymph nodes is confirmed, they should be treated
with radiotherapy.
B
2b
[84 – 90]
e) If patients have an increased cardiac risk or are receiving treatment with trastuzumab, the decision whether
or not to irradiate the internal thoracic artery lymph nodes must be made on an individual basis by an interdisciplinary tumor board.
A
4
[91, 92]
4.46.
Expanded axillary radiation may be used to treat patients with 1–2 affected axillary sentinel lymph nodes if no
axillary dissection is carried out or if the interdisciplinary tumor board agrees that no further local axillary therapy
should be carried out (analogous to ACOSOG Z0011). The decision about the appropriate approach must be
taken by an interdisciplinary tumor board.
0/A
2b
[35, 93 –
95]
4.47.
Radiotherapy of lymph drainage areas should be administered in standard fractions (5 × week 1.8 to 2.0 Gy,
total dose: approx. 50 Gy over a period of approx. 5–6 weeks) or in hypofractionated doses (total dose: approx.
40 Gy in approx. 15–16 fractions over a period of approx. 3 to 5 weeks).
EC
4.48.
Treatment of patients with primary inoperable or inflammatory cancer must consist of primary systemic therapy
followed by surgery and postoperative radiotherapy or, if the cancer continues to be inoperable, radiotherapy
alone or preoperative radiotherapy.
A
1b
[96, 97]
▪ premenopausal and central or medial tumor location and G2–3 and ER/PgR-negative.
b) Irradiation of the supra-/infraclavicular lymph nodes should be carried out in patients with 1–3 affected
lymph nodes in the following circumstances:
▪ central or medial location and (G2–3 or ER/PgR-negative)
▪ premenopausal, lateral location and (G2–3 or ER/PgR-negative)
4.45.
▪ premenopausal and central or medial location and G2–3 and ER/PgR-negative
b) Irradiation of the internal thoracic artery lymph nodes should be carried out in patients with 1–3 affected
lymph nodes in the following circumstances:
▪ central or medial location and (G2–3 or ER/PgR-negative)
▪ premenopausal, lateral location and (G2–3 or ER/PgR-negative)
c) Irradiation of the internal thoracic artery lymph nodes should be carried out in patients with > 3 affected
axillary lymph nodes in the following circumstances:
▪ G2–3 or ER/PgR-negative
1066
Wöckel A et al. Interdisciplinary Screening, Diagnosis, …
Geburtsh Frauenheilk 2018; 78: 1056–1088
No.
4.49.
Recommendations/Statements
EG
LoE
Sources
a) Postoperative chemotherapy and radiotherapy must be administered sequentially.
A
1b
[98 – 101]
Note: No specific sequence (chemotherapy first or radiotherapy first) has been confirmed as superior.
The sequence of chemotherapy followed by radiotherapy is the established sequence in clinical practice.
b) If only RT is administered, treatment with RT should commence within a period of 8 weeks postoperatively.
[102, 103]
c) Adjuvant endocrine therapy can be started independently of any radiotherapy. (1a)
[91, 92,
104, 105]
Therapy with trastuzumab may be continued during radiotherapy. If the patient is receiving simultaneous
irradiation of the internal thoracic artery lymph nodes, the appropriate approach must be decided on by
an interdisciplinary tumor board. (4)
1.3
Systemic adjuvant therapy (endocrine therapy,
chemotherapy, antibody therapy)
1.3.1
Choice of adjuvant therapy and classification
of risk
The 2009 St. Gallen Recommendations have pointed out the significance of endocrine sensitivity and the 2011 Recommendations
have highlighted the importance of molecular subtypes as the decisive criteria whether adjuvant chemotherapy is indicated or not
[106]. The markers ER, PgR, HER2 and Ki-67, which are identified
by immunohistochemistry, are considered surrogate parameters
for different molecular subtypes [106]. ER-positive and/or PgRpositive, HER2-negative tumors with low proliferation rates are
classified as luminal A; if the proliferation rates are high, they are
classified as luminal B. It should be noted that there is currently no
validated threshold value for Ki-67 (e.g. for classifying a tumor as
luminal A vs. luminal B or to confirm the decision for/against adjuvant chemotherapy).
Indications for adjuvant chemotherapy:
▪ simultaneous anti-HER2 therapy with trastuzumab over a period of 1 year combined with (neo-) adjuvant chemotherapy is
the standard approach for HER2-positive tumors
▪ non-endocrine-sensitive tumors (ER- and PgR-negative)
▪ tumors which may not be endocrine-sensitive
▪ node-positive tumors (studies are currently being carried out
to evaluate whether patients with low numbers of affected
lymph nodes [1–3 affected LN] and favorable tumor biology
[luminal A] may not need adjuvant chemotherapy)
▪ G III
▪ young age at onset (< 35 years)
Chemotherapy is always indicated if the individual expected benefit is higher than potential side effects and long-term negative
effects. This requires careful, in-depth counselling and discussions
with the patient, particularly if the expected benefit is minimal.
1.3.2
Endocrine therapy
No.
Recommendations/Statements
EG
LoE
Sources
4.50.
a) Patients with estrogen and/or progesterone receptor-positive* invasive tumors must receive endocrine
therapy.
A
1a
[30, 107 –
110]
b) Endocrine therapy must only be started after chemotherapy has been completed but it can be administered
in parallel to radiotherapy.
A
1a
[30, 45,
107 – 110]
After 5 years of tamoxifen the decision whether or not to continue endocrine therapy must be re-evaluated in
every patient with ER+ breast cancer.
A/B
Adapt.
from
guideline
[111]
A
1a
[107, 108,
112 – 114]
4.51.
When considering whether or not to continue endocrine therapy, the risk of recurrence and the therapy-related
side effects (toxicity, decreased adherence) should be weighed up.
The patientʼs current menopausal status must be taken into account when selecting the appropriate endocrine
therapy.
4.52.
Premenopausal patients must receive tamoxifen therapy for at least 5 years.
Antiestrogen therapy with tamoxifen 20 mg per day must be administered for a period of 5–10 years depending
on the risk of recurrence or until recurrence occurs.
Whether or not expanded therapy is indicated depends on the risk of recurrence and the patientʼs wishes.
4.53.
4.54.
a) High-risk patients with ER+ breast cancer who are still premenopausal after completing chemotherapy may
be treated with an aromatase inhibitor after suppressing ovarian function.
EC
b) Suppression of ovarian function alone can be considered in premenopausal women with ER+ breast cancer
who cannot receive tamoxifen or do not want to be treated with tamoxifen; suppression can be achieved either
by administering a GnRHa or by oophorectomy.
EC
c) Suppression of ovarian function (by GnRHa or bilateral oophorectomy) in addition to tamoxifen or an aromatase inhibitor must only be considered in patients with a high risk of recurrence who are premenopausal after
receiving adjuvant chemotherapy. Suppression of ovarian function is mandatory when treatment consists
of administering aromatase inhibitor.
A
Adapt.
from
guideline
[115]
Adjuvant endocrine therapy for postmenopausal patients with ER+ breast cancer should include an aromatase
inhibitor.
B
1b
[115]
* ≥ 10 % progesterone-receptor-positive tumor cell nuclei
Wöckel A et al. Interdisciplinary Screening, Diagnosis, …
Geburtsh Frauenheilk 2018; 78: 1056–1088
1067
GebFra Science | Guideline
1.3.3
No.
4.55.
Adjuvant chemotherapy
Recommendations/Statements
EG
LoE
Sources
a) Adjuvant chemotherapy is indicated for:
B
1a
[4, 11,
116 – 119]
A
1a
[118,
120 – 124]
B
1b.
[125 –
130]
Adjuvant chemotherapy should include a taxane and an anthracycline.
B
1a
[116, 126,
131 – 139]
6 cycles of TC (docetaxel/cyclophosphamide) may be an alternative in patients with moderate clinical risk
(≤ 3 affected lymph nodes).
0
1a
Standard adjuvant chemotherapy must take 18–24 weeks.
A
1a
LoE
Sources
1a
[140 –
142]
1a
[140, 141,
143, 144]
▪ HER2-positive tumors (from pT1b, N0; pT1a, N0 if additional risks are present: e.g., G3, ER/PR-negative,
high Ki67 levels)
▪ Triple-negative tumors (ER- and PgR-negative, HER2-negative)
Luminal-B tumors with a high risk of recurrence (high Ki-67 levels, G3, high-risk multigene assay, young age
at onset, lymph nodes show tumor involvement)
b) Chemotherapy must be administered in the recommended doses.
Under-dosing or reducing the number of cycles risks reducing the efficacy of chemotherapy.
4.56.
Cytostatic agents may be administered simultaneously or sequentially (according to the evidence-based
protocols).
Dose-dense therapies should be used to treated suitable patients with a high tumor-related risk of mortality.
4.57.
1.3.4
Neoadjuvant therapy
No.
Recommendations/Statements
EG
4.58.
a) Neoadjuvant (primary, preoperative) systemic therapy is considered the standard treatment for patients
with locally advanced, primary inoperable or inflammatory breast cancer in the context of a multimodal therapy
concept.
EC
b) Neoadjuvant systemic therapy should be preferred if the same postoperative adjuvant chemotherapy
is indicated.
EC
4.59.
a) If chemotherapy is indicated, it can be administered prior to surgery (neoadjuvant) or after surgery (adjuvant).
Both approaches are equivalent with regard to overall survival.
Neoadjuvant therapy may lead to a higher rate of breast-conserving therapies.
b) The effect (pathohistological remission) is greatest for hormone receptor-negative cancers.
4.60.
4.61.
c) Resection within the new tumor margins is possible if R0 resection can be achieved.
EC
a) Postmenopausal patients with endocrine-sensitive breast cancer, for whom surgery or chemotherapy is
not possible or who do not want surgery or chemotherapy, may be treated with primary endocrine therapy.
EC
b) Neoadjuvant endocrine therapy is not a standard therapy; neoadjuvant endocrine therapy may be considered
in special situations (inoperable cancer, multiple morbidities).
EC
a) If a neoadjuvant chemotherapy combination is used, it should include an anthracycline and a taxane.
Preoperative therapy should take 18–24 weeks.
EC
HER2-positive tumors for which neoadjuvant chemotherapy is indicated should be treated with trastuzumab.
High-risk (clinical/sonographic findings or N+ on punch biopsy, tumor size > 2 cm) HER2-positive patients should
additionally receive pertuzumab.
4.62.
1068
b) Platinum salts increase the complete remission rate (pCR rate) in patients with triple-negative breast cancer
(TNBC) irrespective of their BRCA status. The benefit for progression-free survival (PFS) and overall survival has
not yet been conclusively confirmed. The toxicity is higher.
EC
If anthracycline-taxane-based neoadjuvant chemotherapy is adequate, no additional adjuvant chemotherapy is
recommended for tumor residues in the breast and/or lymph nodes. Post-neoadjuvant chemotherapy treatment
should only be carried out in the context of clinical trials.
EC
Wöckel A et al. Interdisciplinary Screening, Diagnosis, …
Geburtsh Frauenheilk 2018; 78: 1056–1088
1.3.5
Antibody therapy
No.
Recommendations/Statements
EG
LoE
Sources
4.63.
a) Patients with HER2-overexpressing tumors with a diameter ≥ 1 cm (immunohistochemical score 3+ and/or
ISH-positive) must receive (neo) adjuvant treatment with an anthracycline followed by a taxane in combination
with trastuzumab. Trastuzumab must be administered over a total period of one year.
A
1b
[16, 29,
30]
b) Adjuvant treatment with trastuzumab should preferably be started at the same time as the taxane phase
of adjuvant chemotherapy.
B
2a
[145]
c) If chemotherapy is indicated to treat HER2+ tumors ≤ 5 mm, trastuzumab should be additionally administered.
EC
Six cycles of TCH (docetaxel, carboplatin, trastuzumab) every 3 weeks may also be recommended as an adjuvant
treatment. The cardiotoxicity of this approach is lower than after treatment with anthracyclines
1.3.6
Bone-targeted therapy
1.3.6.1
Therapy and prevention of cancer treatmentinduced bone loss
The risk of bone density loss with destruction of bone structure
and the risk of therapy-related osteoporosis followed by an increased risk of fractures is significantly higher in patients with malignant disease [146]. Apart from such commonly reported
changes as immobilization and changes in lifestyle (e.g. discontinuation of estrogen therapy), it is primarily drug therapies that are
responsible for osseous changes. Supportive therapies (e.g. cortisone preparations) are as likely to damage bones as cytotoxic or
endocrine drugs. This issue is becoming increasingly important
following the high curative rates for many solid tumors, particularly for breast cancer.
In premenopausal women with hormone receptor-positive
breast cancer, ovarian function suppression (e.g. using GnRH analogs) alone or in combination with tamoxifen or an aromatase inhibitor and treatment with tamoxifen alone leads to a loss of bone
density and an increased incidence of osteoporosis compared to
healthy control populations [147 – 149]. The combination of ovarian function suppression with an aromatase inhibitor led to the
greatest decrease in bone density [147].
In postmenopausal women, treatment with aromatase inhibitors also leads to a loss of bone density and an increased incidence of fractures compared to women treated with tamoxifen
[150 – 153].
Chemotherapies can also result in a significant loss of bone
density [154, 155].
The indication for preventive treatment depends on the patientʼs gender, age and bone density and should take the patientʼs
history and lifestyle into account. Primary prevention of cancer
therapy-induced bone loss should be considered if patients
present with a special combination of risks [156, 157]. These include advanced age, low body mass index, nicotine abuse, therapy
with aromatase inhibitors, familial disposition, long-term cortisone therapy, immobility, endocrine disease, medication (Confederation of German-speaking Scientific Osteology Society, http://
www.dv-osteologie.org) [158].
No.
Recommendations/Statements
EG
4.64.
In patients with an increased familial or cancer therapy-related risk of bone loss, bone density measurements
should be carried out prior to starting treatment.
EC
LoE
Sources
Bone density measurements should be repeated at regular intervals depending on the results and the presence
of additional risk factors.
4.65.
Depending on the patientʼs individual combination of risk factors for developing osteoporosis, preventive treatment should be considered to prevent cancer therapy-induced osteoporosis (http://www.dv-osteologie.org;
ESMO bone health guidance).
EC
4.66.
Osteoprotective therapy should be considered for premenopausal patients receiving GnRH and/or TAM
and postmenopausal patients receiving treatment with AI.
B
1b
[147, 150,
152, 158]
4.67.
Hormone therapy with estrogens should not be used to prevent cancer therapy-related osteoporosis in breast
cancer patients as an increased rate of recurrence cannot be excluded, particularly in patients with hormone
receptor-positive disease.
B
1a
[159]
4.68.
In addition to these general recommendations, bisphosphonates or denosumab may be used for primary
prevention of cancer therapy-induced bone loss.
EC
4.69.
A reduced risk of fractures associated with endocrine therapy has only been clearly confirmed for denosumab
but has not yet been confirmed for bisphosphonates.
A
1
[150]
4.70.
Bone-targeted therapy to prevent therapy-related osteoporosis should be carried out for the duration
of endocrine therapy.
EC
Wöckel A et al. Interdisciplinary Screening, Diagnosis, …
Geburtsh Frauenheilk 2018; 78: 1056–1088
1069
GebFra Science | Guideline
1.3.6.1.1 Therapy for cancer therapy-induced osteoporosis
No.
Recommendations/
Statements
EG
4.71.
It is important to exclude bone
metastasis if a bone fracture
occurs which was not caused by
sufficiently powerful trauma.
EC
1.3.6.2
LoE
Sources
Adjuvant therapy to improve bone metastasis-free
survival and overall survival
According to the “seed and soil” hypothesis, luminal breast cancer
cells are particularly prone to metastasize in bone where they are
then detected in the form of disseminated tumor cells [160 –
162]. Bisphosphonates and probably also denosumab appear to
have a therapeutic effect with regard to the persistence of these
cells and thus on the incidence of secondary bone metastasis
[163].
Two meta-analyses evaluated studies on the adjuvant use of
different bisphosphonates. Ben-Aharon and colleagues found a
positive effect on survival in postmenopausal patients with breast
cancer (HR 0.81 [0.69–0.95]) [164]. In their meta-analysis, Coleman and colleagues reported a significant positive effect on bone
metastasis-free survival of 34 % and on overall survival of 17 % for
postmenopausal patients (including premenopausal patients with
ovarian function suppression from GnRH analogs; ABCSG-12)
[165].
The meta-analyses found no significant benefit for premenopausal patients (without ovarian function suppression from GnRH
analogs) with regard to disease-free survival, bone metastasis-free
survival and overall survival. No effect on prognosis was detected
in an evaluation of a secondary endpoint carried out in a subpopulation of premenopausal patients (the majority of whom did not
have suppression of ovarian function), despite the high therapy
density at the start of treatment (AZURE trial [158]).
To date, no bisphosphonate has been approved for use in adjuvant therapy in the European Union, meaning that treatment can
currently only be carried out as an off-label use.
No.
Recommendations/
Statements
EG
LoE
Sources
4.72.
Adjuvant bisphosphonate therapy prolongs bone metastasisfree survival and overall survival
in postmenopausal patients with
breast cancer and in premenopausal patients with ovarian
function suppression (off-label
use).
A
1
[164,
165]
4.73.
It is currently not possible to recommend the adjuvant use of
bisphosphonates or denosumab
for premenopausal patients with
suppression of ovarian function.
0
1b
[158,
164,
165]
1.3.6.3
Bone-targeted therapy for patients
with bone metastasis
The most common metastases of breast cancer occur in bone
marrow. Luminal tumors have a particular affinity to the skeleton.
The most common complications of bone metastases are pain,
pathological fractures, vertebral compression syndrome, and hypercalcemia [166]. If the aforementioned symptoms (with the exception of pain) occur, then morbidity is significantly increased. A
number of different measures can be initiated to prevent these
serious complications.
The interdisciplinary AWMF S3 guideline 032-054OL “Supportive Therapy for Oncology Patients” provides a detailed discussion
of the diagnosis and therapy of bone metastases [167]).
No.
Recommendations/
Statements
EG
4.74.
Patients must go to the dentist
before starting adjuvant osteoprotecttive therapy. The Recommendations of the S3 guideline
on “Antiresorptive drug-related
necrosis of the jaw” apply.
EC
1.3.7
LoE
Sources
Lifestyle factors which can be influenced
No.
Recommendations/Statements
EG
LoE
Sources
4.75.
Patients must be motivated to carry out physical exercise and to normalize their body weight (if their BMI is high).
Patients should receive support and assistance. It is particularly recommended that patients:
A
2a/1a
[168 –
171]
a) avoid physical inactivity and return to normal daily activities as early as possible after diagnosis (LoE 2a)
b) work towards achieving the goal of 150 minutes of moderate or 75 minutes of strenuous physical activity
per week (LoE 1a)
4.76.
Patients should be offered weight training programs, particularly when they are undergoing chemotherapy
and hormone therapy.
B
1b
[172 –
175]
4.77.
Patients should be advised and taught to do regular sports activities and physical exercise to treat breast cancerassociated fatigue.
B
1a
[176 –
179]
1070
Wöckel A et al. Interdisciplinary Screening, Diagnosis, …
Geburtsh Frauenheilk 2018; 78: 1056–1088
No.
Recommendations/Statements
EG
LoE
Sources
4.78.
If manifest chemotherapy-induced polyneuropathy is present, patients should have exercise therapy to improve
functionality.
B
1a/2a
[173, 174,
180, 181]
This may include:
▪
▪
▪
▪
▪
balance exercises
sensorimotor training
coordination training
vibration training
fine motor skills training
4.79.
Patients with lymphedema after surgery for breast cancer must be started on monitored, gradually progressive
weight training to treat lymphedema.
B
1b
[182 –
187]
4.80.
Patients should be counselled (a) about achieving and maintaining a healthy body weight, and (b) if they are
overweight or obese, about how to limit their consumption of highly-calorific food and drinks and how
to increase their physical activity to promote moderate weight loss and maintain it over the long-term.
A
Adapt.
From
guideline
[188]
4.81.
Patients should be counselled on how to achieve and adhere to a nutritional program rich in vegetables, fruit,
wholegrain and pulses which contains few saturated fats and only limited alcohol consumption.
A
Adapt.
from
guideline
[188]
4.82.
Patients must receive counselling not to smoke; if necessary, smokers must be recommended smoking cessation
programs.
A
2a
[188]
4.83.
To prevent late recurrence (> 5 years after primary diagnosis), patients with receptor-positive disease should
avoid a daily alcohol consumption of > 12 g pure alcohol.
B
2a
[189]
1.4
Breast cancer during pregnancy and lactation, pregnancy after breast cancer, fertility preservation
1.4.1
Pregnancy after breast cancer
No.
Recommendations/Statements
EG
LoE
Sources
7.1.
Patients who have had breast cancer must not be counselled against becoming pregnant. This applies irrespective of their hormone status.
A
3a
[190, 191]
7.2.
a) The interval until becoming pregnant after breast cancer is not correlated with a poorer prognosis.
A
3a
[190]
b) The risk of recurrence depends on the tumor biology and the stage of disease. This must be discussed during
counselling for any subsequent pregnancy.
EC
7.3.
The longer the endocrine therapy, the better the chances for a cure (see Chapter 4.7.2 Endocrine therapy).
If the patient wished to become pregnant before completing endocrine therapy, then endocrine therapy should
be continued after the patient has given birth and stopped breastfeeding.
EC
7.4.
a) Patients can try to become pregnant after breast cancer with the help of reproductive medical procedures.
0
4
[192 –
194]
2c
[195]
LoE
Sources
b) The chances of success (i.e. an intact pregnancy or baby) are lower for breast cancer patients when autologous
eggs are used compared to women without breast cancer.
1.4.2
Breast cancer during pregnancy
No.
Recommendations/Statements
EG
7.5.
a) Treatment (systemic therapy, surgery, RT) for breast cancer (in pregnant patients) during pregnancy must be
as similar as possible to treatment administered to younger, non-pregnant patients with breast cancer.
EC
b) Standard chemotherapy with anthracyclines and taxanes may be administered in the 2nd and 3rd trimester
of pregnancy.
0
2b
[196 –
200]
c) Anti-HER2 therapy must not be administered during pregnancy.
A
3a
[196, 197,
199]
d) Endocrine therapy must not be administered during pregnancy.
EC
e) Surgery may be carried out in the same way as in non-pregnant patients.
EC
Wöckel A et al. Interdisciplinary Screening, Diagnosis, …
Geburtsh Frauenheilk 2018; 78: 1056–1088
1071
GebFra Science | Guideline
1.4.3
Fertility preservation
No.
Recommendations/Statements
EG
7.6.
a) Patients of childbearing age with breast cancer must receive counselling about fertility and preserving fertility
before starting cancer treatment.
EC
b) The administration of a GnRH analog before starting chemotherapy may be considered in all women who wish
to preserve their ovarian function/fertility.
1.5
Breast cancer in older patients
1.5.1
General comments
LoE
Sources
0
1b
[200 –
206]
LoE
Sources
No.
Recommendations/Statements
EG
8.1.
Therapeutic decisions for older patients should be based on current standard recommendations but also take
account of the patientʼs biological age, life-expectancy and preferences; the benefits and risks of such therapy
must be weighed up.
EC
1.5.2
Geriatric patients
No.
Recommendations/Statements
EG
LoE
Sources
8.2.
Patients who are older than 75 years should have a geriatric assessment or screening using a geriatric assessment
algorithm, particularly if chemotherapy or surgery requiring a general anesthetic is planned, with the aim
of improving therapy adherence, tolerance of chemotherapy and possibly survival.
B
2a
[207 –
210]
8.3.
Geriatric assessment and management should cover therapy-relevant geriatric domains (particularly functionality-related parameters such as activities of daily living, mobility, cognition, falls, and morbidity-related
parameters such as multiple medication, nutrition, fatigue, and number of comorbidities) in order to adapt the
choice of therapy accordingly and start supportive measures.
B
2a
[30, 211 –
214]
LoE
Sources
1b
[215]
1.5.3
Local therapy
No.
Recommendations/Statements
EG
8.4.
a) Surgical therapy to treat older patients is basically no different from the surgical therapy used to treat younger
patients.
EC
b) Patients with ER/PR-positive breast cancer: primary endocrine therapy should be started if surgery is not carried out because of the patientʼs frailty (e.g., comorbidities and higher anesthetic risk) or because the patient
rejects surgery. When deciding on the appropriate therapy, any drug-related specific side effects, particularly the
risk of thrombosis/embolism (tamoxifen) and the risk of bone fractures (aromatase inhibitors), must be taken
into consideration.
B
c) Patients with ER- and PR-negative breast cancer: if surgery under general anesthesia is not carried out because
of the patientʼs frailty (e.g. comorbidities and increased surgical risk) or because the patient rejects surgery,
surgery under local anesthesia, primary radiotherapy or purely palliative medical treatment may be considered.
EC
1.5.4
Adjuvant endocrine therapy
No.
Recommendations/Statements
EG
LoE
Sources
8.5.
Endocrine therapy is recommended for patients with hormone receptor-positive disease. Endocrine therapy may
be dispensed with in individual cases (i.e., when treating patients with very low-grade tumors or very favorable
tumor biology or if the patient is very frail).
0
2b
[213, 216]
1072
Wöckel A et al. Interdisciplinary Screening, Diagnosis, …
Geburtsh Frauenheilk 2018; 78: 1056–1088
1.5.5
Adjuvant chemotherapy
No.
Recommendations/Statements
EG
8.6.
As patients become frailer with increasing age, their reduced physical reserves and changes in their pharmacokinetics may lower the tolerability of chemotherapy and increase the rate of side effects requiring treatment.
EC
8.7.
Chemotherapy may be associated with a significant reduction in cognitive performance in older women aged
> 70 years.
8.8.
Preference should be given to anthracycline and/or taxane-based combinations or sequential regimens. The increased risk of cardiotoxicity and of MDS/AML associated with anthracyclines must be taken into consideration.
1.5.6
LoE
Sources
2b
[217, 218]
B
2a
[219 –
227]
EG
LoE
Sources
EC/1b
[214,
228 – 230]
2b
[231, 232]
Anti-HER2 therapy
No.
Recommendations/Statements
8.10.
Treatment is analogous to the treatment administered to younger patients and consists of trastuzumab
combined sequential anthracycline-taxane-based chemotherapy.
It is important to be aware of the increased risk of cardiotoxicity associated with this approach. (EC)
An anthracycline-free combination consisting of carboplatin-docetaxel or docetaxel-cyclophosphamide
may be used. (1b)
8.11.
1.6
Paclitaxel administered weekly (over 12 weeks) with trastuzumab may be used to treat T1–2 (up to 3 cm) pN0
tumors.
Breast cancer in men
Breast cancer in men should be diagnosed and treated by an interdisciplinary group of specialists. Because of the type of tumor biology and the similarities to breast cancer in women, specialists
for gynecologic oncology must also be involved when treating
breast cancer in men. An interdisciplinary cooperation between
0
breast centers, gynecologists, urologists and andrologists is particularly advisable when treating sexual disorders caused by therapy with tamoxifen, men with BRCA mutations [233] who have an
increased associated risk of prostate cancer, and men with breast
cancer who must be treated for benign prostate syndrome [234].
No.
Recommendations/Statements
EG
9.1.
a) Patients must be encouraged to ask for medical counselling early on and provided with information about
disease, particularly about symptoms and changes in the breast; they must be encouraged to monitor themselves.
EC
LoE
Sources
b) If there is a suspicion of malignancy, the initial investigation must include taking the patientʼs history, clinical
examination, mammography, and ultrasound examination of the breast and of the lymphatic drainage areas.
There are no data on the diagnostic use of CM‑MRI.
c) If there are malignant findings in the breast and axilla, further examinations with staging/investigation into the
extent and spread of disease must be carried out in accordance with the recommendations made for women in
the same situation, although there are no data on the diagnostic use of CM‑MRI.
9.2.
a) The aim of surgery is complete resection of the tumor. Surgery should consist of a mastectomy.
Breast-conserving surgery should be considered if the tumor is small enough.
EC
b) If the axilla are clinically unremarkable (cN0), sentinel lymph node resection must be carried out, with the same
rules applying as for women.
9.3.
Irrespective of surgery, adjuvant radiotherapy of the thoracic wall and, if necessary, of the lymphatic drainage
areas (the indications for this are the same as for women) must be carried out to treat large tumors (≥ 2 cm) and
axillary lymph node involvement if the hormone receptor status is negative.
EC
9.4.
When deciding whether adjuvant chemotherapy and antibody therapy (anti-HER2) are indicated, the same rules
apply as for women and the same therapy must be carried out.
EC
9.5.
Patients with hormone receptor-positive breast cancer must receive adjuvant endocrine therapy with tamoxifen,
usually over a period of 5 years. There are no data available about treatment for more than 5 years. It may be
considered in individual cases in the same way it would be considered when treating women.
EC
a) Metastatic disease should be treated according to the same rules as those used to treat women.
EC
9.6.
b) It is not clear whether aromatase inhibitors are sufficiently effective in men without suppression of testicular
function. Aromatase inhibitors should therefore be administered together with suppression of testicular function.
Wöckel A et al. Interdisciplinary Screening, Diagnosis, …
Geburtsh Frauenheilk 2018; 78: 1056–1088
1073
GebFra Science | Guideline
No.
Recommendations/Statements
EG
9.7.
Men with breast cancer should be offered the opportunity to participate in trials/be included in tumor
registers.
EC
9.8.
Genetic testing must be recommended to all men with breast cancer.
EC
9.9.
The follow-up regimen including imaging evaluations must be analogous to the approach used for women.
EC
9.10.
The patient should be provided with qualified and relevant gender-specific information (in print and online)
by the professionals who treat them, and the patient should be helped to access the targeted support and information available from self-help groups.
EC
LoE
Sources
▶ Table 5 Risk factors for men to develop breast cancer.
Age
Unimodal age distribution; the highest incidence is in the 71st year of life
Ethnicity
Increased risk for men of African or Caribbean descent, who usually also have an advanced stage of disease
when they are first diagnosed
Germline mutations
If the patientʼs family has a positive history of germline mutations for both sexes, they have a 2.5-fold higher risk of disease;
BRCA-2 mutations were confirmed in 4–40 % of all cases; RAD51B gene modifications increase the risk by 50 %
Endocrine causes
Exposure to exogenous estrogen, e.g. hormone therapy for transsexuals, treatment of prostate cancer, professional exposure
Increased endogenous estrogen synthesis: Klinefelter syndrome, obesity
Decreased levels of androgen: orchiectomy, undescended testicle, mumps orchitis, cirrhosis of the liver
Environment
Lifestyle: obesity, lack of exercise, excessive consumption of alcohol
Exposure to radiation: nuclear weapons, radiotherapy, diagnostic radiology
Professional exposure: high temperatures, petroleum, exhaust gases
2
Therapy (Recurrence/Metastasis)
2.1
2.1.1
Therapy for local/loco-regional recurrence
Local (intramammary) recurrence
No.
Recommendations/Statements
EG
5.7.
a) If there is a suspicion of loco-regional recurrence, the first step must be histological verification including
repeat determination of ER, PR and HER2/neu status and complete re-staging to exclude metastasis and make it
possible to plan an interdisciplinary therapy strategy.
EC
b) The highest level of local tumor control in patients with intramammary recurrence (DCIS/invasive carcinoma)
is achieved by secondary mastectomy.
EC
c) If the initial situation is favorable (e.g. DCIS or invasive carcinoma with a lengthy recurrence-free interval
and no skin involvement), then breast-conserving surgery can be carried out again after careful counselling
of the patient.
0
d) Prior to carrying out another breast-conserving surgery, the possibility of carrying out repeat radiotherapy
(partial breast irradiation) should be investigated and discussed by an interdisciplinary tumor conference;
if necessary, the patient should have an appointment with a radiotherapist.
EC
e) After breast-conserving surgery, the patient must be informed about the increased risk of repeat intramammary recurrence.
EC
2.1.2
Sources
4a
[235 –
238]
LoE
Sources
Local recurrence after mastectomy
No.
Recommendations/Statements
EG
5.8.
Any isolated recurrence in the thoracic wall must be completely resected (R0) where possible. If the main site
of recurrence is the ribs/intercostal muscles, the decision for therapy should be taken after interdisciplinary
consultation with a specialist for thoracic surgery.
EC
5.9.
Local therapy (surgical intervention, radiotherapy) may be considered for symptomatic local recurrence
(e.g. ulceration, pain) to reduce symptoms, even if the patient has distant metastasis.
EC
1074
LoE
Wöckel A et al. Interdisciplinary Screening, Diagnosis, …
Geburtsh Frauenheilk 2018; 78: 1056–1088
2.1.3
Axillary lymph node recurrence
No.
Recommendations/Statements
EG
5.10.
In the event of axillary lymph node recurrence, local recurrence of disease should be controlled by repeat surgical
axillary intervention, if need be with radiotherapy. Thoracic CT should be done preoperatively to identify the
extent of LN metastasis.
EC
2.1.4
Sources
LoE
Sources
LoE
Sources
Drug therapy
No.
Recommendations/Statements
EG
5.11.
Systemic therapy after R0 resection of loco-regional recurrence must be considered to prolong the disease-free
interval and overall survival.
EC
2.1.5
LoE
Radiotherapy
No.
Recommendations/Statements
EG
5.12.
a) The question whether radiation is indicated after surgery for recurrence must be discussed and decided
by an interdisciplinary tumor board.
EC
Postoperative radiotherapy should be carried out if no radiotherapy was carried out previously or if the local
recurrence was not radically resected (R1–2).
b) Palliative radiotherapy, if necessary in combination with chemotherapy, may be used to treat inoperable local
recurrence and control symptoms.
EC
c) If there is intramammary recurrence or recurrence in the thoracic wall after breast-conserving surgery (R0)
or mastectomy (R0) which was not followed by radiotherapy, the decision whether adjuvant radiotherapy is
indicated must follow the recommendations for primary disease.
EC
d) If intramammary recurrence occurs after breast-conserving surgery (R0) followed by radiotherapy, the question whether adjuvant radiotherapy is indicated must be discussed by an interdisciplinary tumor board. Radiotherapy may be indicated for patients who did not experience serious late sequelae after the 1st radiotherapy.
EC
e) In the event of recurrence in the thoracic wall after mastectomy (R0) followed by radiotherapy, the question
whether repeat radiotherapy is indicated for local control should be discussed by an interdisciplinary tumor
board.
EC
f) In the event of recurrence in the thoracic wall after primary mastectomy without subsequent radiotherapy,
adjuvant radiotherapy should be carried out after resection of the recurrence (R0) if additional risk factors are
present (very small resection margins, rpN+, G3, lymph node invasion).
EC
g) In the event of recurrence in the thoracic wall after primary mastectomy without subsequent radiotherapy, the
question whether repeat adjuvant radiotherapy is indicated after resection of the recurrence (R0) when additional risk factors are present (very small resection margins, rpN+, G3, lymph node invasion) should be discussed
by an interdisciplinary tumor board. Radiotherapy may be indicated for patients who did not experience serious
late sequelae after the 1st radiotherapy.
EC
h) Additional radiotherapy must be recommended if recurrence occurs in an area which was not previously
irradiated, the recurrence was not completely resected (R1/R2), and the risk associated with complete surgical
resection (R0) cannot be justified.
EC
i) An interdisciplinary tumor board must decide whether repeat radiotherapy is indicated when recurrence
occurs after prior radiotherapy, the recurrence was not completely resected (R1/R2), and the risk associated with
complete surgical resection (R0) cannot be justified.
EC
Radiotherapy may be indicated in patients who did not experience serious late sequelae after the 1st radiotherapy.
2.2
Distant metastases
2.2.1
Systemic therapy for metastatic breast cancer
No.
Recommendations/Statements
EG
LoE
Sources
5.13.
Endocrine therapy ± targeted therapy is the therapy of choice for patients with hormone receptor-positive and
HER2-negative cancer. Endocrine therapy is not indicated in patients for whom rapid remission is important
to avoid pronounced symptoms in the affected organ.
A
1b
[30, 239 –
243]
Wöckel A et al. Interdisciplinary Screening, Diagnosis, …
Geburtsh Frauenheilk 2018; 78: 1056–1088
1075
GebFra Science | Guideline
No.
Recommendations/Statements
EG
LoE
Sources
5.14.
Combined chemo-endocrine therapy is not recommended. Although this approach can increase the rate
of remission, it also leads to increased toxicity without prolonging the progression-free interval or improving
overall survival.
A
1a
[244]
5.15.
In premenopausal patients, suppression of ovarian function (with GnRH analogs, oophorectomy) combined with
tamoxifen is the first-choice therapy if treatment with tamoxifen was not concluded less than 12 months previously. An alternative approach consisting of suppression of ovarian function followed by the same treatment as
that recommended for postmenopausal women may be chosen, and endocrine therapy may be combined with
CDK 4/6 inhibitors.
A
1b
[30, 242,
245, 246]
5.16.
Subsequently, ovarian suppression combined with an aromatase inhibitor or fulvestrant, if necessary in
combination with palbociclib, can be used to treat premenopausal patients. As long as ovarian suppression
is maintained, treatment may be administered in the same way as therapy for postmenopausal patients.
0
2c/EC
[247, 248]
5.17.
In postmenopausal patients, the first step of endocrine treatment for metastasis should consist of an aromatase
inhibitor if adjuvant therapy consisted exclusively of tamoxifen or the patient did not receive adjuvant therapy.
It is not possible to give a clear recommendation whether primary endocrine treatment should consist of a
steroidal or a non-steroidal aromatase inhibitor. Letrozole may be combined with a CDK 4/6 inhibitor.
A
1a
[30, 239,
242, 249 –
252]
5.18.
Treatment with fulvestrant should be carried out after pretreatment with an aromatase inhibitor, although
fulvestrant may also be used as a first-line therapy, particularly for patients who have not previously received
endocrine therapy.
EC
5.19.
No specific therapy sequence is recommended. A combination treatment consisting of letrozole or fulvestrant
with a CDK 4/6 inhibitor represents an alternative to monotherapy.
EC
LoE
Sources
Follow-up therapy with exemestane and the mTOR inhibitor everolimus may be administered after anti-hormonal pretreatment with a non-steroidal aromatase inhibitor.
Studies have shown that combination therapies prolonged progression-free survival but it has not yet been
proven that they improve overall survival.
5.20.
EC
Depending on the patientʼs previous treatment, the next steps in the endocrine treatment sequence for postmenopausal patients consist of administration of antiestrogens, estrogen receptor antagonists, switching from
a steroidal to a non-steroidal aromatase inhibitor or vice versa, or the use of high-dose progestogens.
If disease progression continues during treatment with a non-steroidal aromatase inhibitor, patients may treated
with a combination of letrozole or fulvestrant with palbociclib or a combination of exemestane and everolimus.
2.2.2
Chemotherapy for metastatic breast cancer
No.
Recommendations/Statements
EG
5.21.
Before starting chemotherapy, the patientʼs general condition, co-morbidities and previous therapies
must be evaluated and her probable compliance with treatment must be assessed.
EC
5.22.
Regular evaluations of toxicity (subjective and objective) must be carried out during therapy. Treatment doses
and scheduled treatment intervals must follow generally accepted standard regimens or recently published
therapy regimens. After determining suitable representative parameters (symptoms, tumor markers, imaging)
prior to starting therapy, the effect of treatment must be evaluated at least every 6–12 weeks according to
clinical requirements. Over time, the intervals between imaging procedures can be extended for patients with
sustained remission and a good clinical and laboratory assessment of disease status.
EC
Therapy should be discontinued if the patient has clinically relevant progression or toxicity is intolerable.
EC
5.23.
Patients should not change to a different chemotherapy regimen unless the patient has documented progression
or toxicity is intolerable.
5.24.
2.2.2.1
a) If chemotherapy is indicated, patients not in need of rapid remission should receive sequential chemotherapy.
B
1a
[253, 254]
b) A combination therapy consisting of chemotherapy and bevacizumab may improve progression-free survival
as a first-line therapy, but this approach is associated with a higher rate of side effects and has no impact on
overall survival.
0
1a
[255 –
260]
c) Polychemotherapy or chemotherapy + bevacizumab may be administered to patients with severe symptoms
and rapid tumor growth or aggressive tumor behavior, i.e. to patients who urgently require remission.
0
1a
[253, 261]
Bevacizumab for metastatic breast cancer (1st line)
In summary, higher rates of remission and an improved PFS (but
no survival benefit) has been reported for additional therapy with
bevacizumab, which seems to indicate that combination therapy
is the appropriate treatment for patients in urgent need of remis-
1076
sion and no combination of risk factors predisposing them to side
effects (no previous history of uncontrolled arterial hypertension,
cerebrovascular ischemia and deep vein thrombosis). See the long
version for more details.
Wöckel A et al. Interdisciplinary Screening, Diagnosis, …
Geburtsh Frauenheilk 2018; 78: 1056–1088
2.2.2.2
2.2.4.2.1 Indications for radiotherapy
Regimens
Specific information on the regimens are available in the long version of this guideline (in German).
No.
Recommendations/
Statements
EG
5.25.
Possible monotherapies can consist of the following substances:
alkylating agents, anthraquinones, anthracyclines (also in
liposomal form), eribulin, fluoropyrimidine, platinum complexes,
taxanes, and vinorelbine. These
substances can be combined
with each another or with further
substances for polychemotherapy. However, patients
should only be treated with combinations that have previously
been investigated in trials.
EC
2.2.3
LoE
Sources
Recommendations/
Statements
EG
5.30.
Indications for local percutaneous radiotherapy for bone
metastasis are:
EC
LoE
Sources
LoE
Sources
LoE
Sources
▪ local pain,
▪ limited mobility,
▪ reduced stability (danger
of fractures),
▪ s/p surgical stabilization,
▪ impending or existing neurological symptoms (e.g. compression of the spinal cord).
2.2.4.2.2 Indications for surgical therapy
Metastatic HER2-positive breast cancer
No.
Recommendations/
Statements
EG
LoE
Sources
5.26.
Systemic therapy after R0 resection of loco-regional recurrence
must be considered to prolong
the disease-free interval and
overall survival.
B
1a
[262,
263]
5.27.
First-line therapy for metastasized HER2-positive breast
cancer should consist of a dual
blockade with trastuzumab/
pertuzumab and a taxane.
B
1b
[262]
5.28.
Second-line therapy for metastasized HER2-positive breast
cancer should consist of therapy
with T‑DM1.
B
1b
[262]
No.
Recommendations/
Statements
EG
5.31.
Indications for the surgical therapy of osseous manifestations
may be:
EC
▪ myeloid compression with
neurological symptoms,
▪ pathological fracture,
▪ impending fracture (risk of
fracture, e.g. based on Mirelsʼ
scoring system, the Spinal
Instability Neoplastic Scale
[SINS]),
▪ solitary late metastasis,
▪ osteolysis which does not
respond to radiotherapy,
▪ pain which does not respond
to treatment.
2.2.4.2.3 Osteoprotective therapy
2.2.4
Specific locations of metastases
2.2.4.1
Basic approach for distant metastasis
No.
Recommendations/
Statements
EG
5.29.
The decision whether distant
metastases should be treated
with surgery or local ablation
should be made on an individual
basis by an interdisciplinary
tumor board.
EC
2.2.4.2
No.
LoE
No.
Recommendations/
Statements
EG
5.32.
Osteoprotective therapy with
bisphosphonates/denosumab
should be carried out to prevent
complications from osseous
manifestations.
EC
Sources
Special treatment for skeletal metastases
For the diagnosis and therapy of skeletal metastasis, please refer
to the S3 guideline on Supportive Therapy for Oncology Patients
(http://leitlinienprogramm-onkologie.de/Supportive-Therapie.
95.0.html).
Wöckel A et al. Interdisciplinary Screening, Diagnosis, …
Geburtsh Frauenheilk 2018; 78: 1056–1088
1077
GebFra Science | Guideline
2.2.4.3
Treatment for brain metastasis
No.
Recommendations/Statements
5.26.
▪ Single or solitary brain metastases should be resected if the patient has an otherwise favorable prognosis and
the metastasis is in a location which permits its resection, and the risk of postoperative neurological deficits
resulting from resection is low. Local fractionated radiotherapy or radiosurgery of the tumor bed should be
subsequently carried out.
▪ Radiosurgery represents an alternative to resection for patients with single metastases if the metastases are
not larger than 3 cm and there is no midline shift with symptoms of intracranial compression.
▪ Primary treatment of infratentorial metastasis consists of resection, which should be carried out to prevent
imminent occlusive hydrocephalus.
▪ If the patient only has a limited number of brain metastases (between 2–4) and their total volume can be
treated with targeted radiation, initial radiosurgery is preferable to whole brain radiation therapy because
of the lower negative impact on neurocognition, the shorter treatment time, and the better control rates.
If surgery or radiosurgery cannot be carried out because of other negative prognostic criteria, the patient must
receive whole brain radiation therapy alone. Whole brain radiation therapy alone must be used to treat
patients with multiple brain metastases.
▪ A combination of resection or radiosurgery with whole brain radiation therapy improves the brain-specific
progression-free survival compared to surgery or radiosurgery alone but does not improve overall survival.
However, this approach can be considered in individual cases.
▪ It is not necessary to combine whole brain radiation therapy with radiosensitizing drugs.
No.
Recommendations/Statements
EG
5.34.
If cerebral metastasis is present, the patient should also receive systemic therapy (chemotherapy/endocrine
therapy/anti-HER2 therapy) in addition to local therapy (surgery/radiotherapy).
EC
2.2.4.4
EG
LoE
Sources
1b/EC
[264 –
273]
LoE
Sources
2.2.4.5.1 Malignant pleural effusion
Treatment for liver metastases
No.
Recommendations/
Statements
EG
LoE
Sources
No.
Recommendations/
Statements
EG
LoE
Sources
5.35.
If the patient has liver metastases, resection or another form
of local therapy (RFA, TACE,
SBRT, SIRT) may be indicated in
individual cases; the preconditions for this are:
0
3b
[274 –
285]
5.37.
Patients with pleural carcinosis
and symptomatic pleural effusions must be offered pleurodesis.
A
1a
[291]
LoE
Sources
▪ no disseminated metastases
▪ controlled extrahepatic
metastasis
2.2.4.5
2.2.4.6
Treatment for lung metastases
No.
Recommendations/
Statements
EG
LoE
Sources
5.36.
Resection or another local therapy (RFA, stereotactic radiotherapy) may be indicated to treat
individual patients with lung
metastases; the preconditions
for this are:
0
4
[286 –
290]
▪ no disseminated metastases
▪ controlled extrapulmonary
metastasis
1078
Skin and soft tissue metastasis
No.
Recommendations/
Statements
EG
5.34.
Surgical excision or another form
of local therapy (e.g. radiotherapy) can be considered to treat
skin and soft tissue metastasis.
EC
Conflict of Interest
See https://www.leitlinienprogramm-onkologie.de/leitlinien/
mammakarzinom/
Wöckel A et al. Interdisciplinary Screening, Diagnosis, …
Geburtsh Frauenheilk 2018; 78: 1056–1088
References
[1]
[2]
[3]
Moran MS, Schnitt SJ, Giuliano AE et al. Society of Surgical OncologyAmerican Society for Radiation Oncology consensus guideline on margins for breast-conserving surgery with whole-breast irradiation in
stages I and II invasive breast cancer. J Clin Oncol 2014; 32: 1507–1515
Department of Health. Diagnosis, staging and treatment of patients
with breast cancer. National Clinical Guideline No. 7. June 2015. ISSN
2009-6259. Online: https://www.hse.ie/eng/services/list/5/cancer/
profinfo/guidelines/breast/; last access: May 2016
Houssami N, Macaskill P, Marinovich ML et al. The association of surgical
margins and local recurrence in women with early-stage invasive breast
cancer treated with breast-conserving therapy: a meta-analysis. Ann
Surg Oncol 2014; 21: 717–730
[18] Gentilini O, Botteri E, Rotmensz N et al. Conservative surgery in patients
with multifocal/multicentric breast cancer. Breast Cancer Res Treat
2009; 113: 577–583
[19] Lynch SP, Lei X, Hsu L et al. Breast cancer multifocality and multicentricity and locoregional recurrence. Oncologist 2013; 18: 1167–1173
[20] Neri A, Marrelli D, Megha T et al. Clinical significance of multifocal and
multicentric breast cancers and choice of surgical treatment: a retrospective study on a series of 1158 cases. BMC Surg 2015; 15: 1
[21] Patani N, Carpenter R. Oncological and aesthetic considerations of conservational surgery for multifocal/multicentric breast cancer. Breast J
2010; 16: 222–232
[22] Shaikh T, Tam TY, Li T et al. Multifocal and multicentric breast cancer is
associated with increased local recurrence regardless of surgery type.
Breast J 2015; 21: 121–126
[23] Tan MP, Sitoh NY, Sim AS. Breast conservation treatment for multifocal
and multicentric breast cancers in women with small-volume breast tissue. ANZ J Surg 2017; 87: E5–E10. doi:10.1111/ans.12942
[4]
Early Breast Cancer Trialistsʼ Collaborative Group (EBCTCG). Effects of
chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet
2005; 365: 1687–1717
[5]
Fisher B, Anderson S, Tan-Chiu E et al. Tamoxifen and chemotherapy for
axillary node-negative, estrogen receptor-negative breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B‑23.
J Clin Oncol 2001; 19: 931–942
[24] Wolters R, Wöckel A, Janni W et al. Comparing the outcome between
multicentric and multifocal breast cancer: what is the impact on survival,
and is there a role for guideline-adherent adjuvant therapy? A retrospective multicenter cohort study of 8,935 patients. Breast Cancer Res Treat
2013; 142: 579–590
[6]
Veronesi U, Cascinelli N, Mariani L et al. Twenty-year follow-up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer. N Engl J Med 2002; 347: 1227–1232
[25] Yerushalmi R, Tyldesley S, Woods R et al. Is breast-conserving therapy a
safe option for patients with tumor multicentricity and multifocality?
Ann Oncol 2012; 23: 876–881
[7]
Fisher B, Anderson S, Bryant J et al. Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy
plus irradiation for the treatment of invasive breast cancer. N Engl J Med
2002; 347: 1233–1241
[26] Rhiem K, Engel C, Graeser M et al. The risk of contralateral breast cancer
in patients from BRCA1/2 negative high risk families as compared to patients from BRCA1 or BRCA2 positive families: a retrospective cohort
study. Breast Cancer Res 2012; 14: R156
[8]
Wald NJ, Murphy P, Major P et al. UKCCCR multicentre randomised controlled trial of one and two view mammography in breast cancer screening. BMJ 1995; 311: 1189–1193
[27] Fayanju OM, Stoll CR, Fowler S et al. Contralateral prophylactic mastectomy after unilateral breast cancer: a systematic review and meta-analysis. Ann Surg 2014; 260: 1000–1010
[9]
Weaver DL, Krag DN, Ashikaga T et al. Pathologic analysis of sentinel and
nonsentinel lymph nodes in breast carcinoma: a multicenter study. Cancer 2000; 88: 1099–1107
[28] Kurian AW, Lichtensztajn DY, Keegan TH et al. Use of and mortality after
bilateral mastectomy compared with other surgical treatments for
breast cancer in California, 1998–2011. JAMA 2014; 312: 902–914
[10] McCahill LE, Single RM, Aiello Bowles EJ et al. Variability in reexcision following breast conservation surgery. JAMA 2012; 307: 467–475
[29] Potter S, Brigic A, Whiting PF et al. Reporting clinical outcomes of breast
reconstruction: a systematic review. J Natl Cancer Inst 2011; 103: 31–46
[11] New Zealand Guidelines Group (NZGG). Management of Early Breast
Cancer – Evidence-based Best Practice Guideline. New Zealand Guidelines Group (2009). Online: https://www.health.govt.nz/system/files/
documents/publications/mgmt-of-early-breast-cancer-aug09.pdf; last
access: 01.09.2016
[30] The National Institute for Health and Care Excellence (NICE). Advanced
breast cancer: diagnosis and treatment. 2009 [addendum 2014].
Online: https://www.nice.org.uk/guidance/cg81/evidence/addendum242246990
[12] Fisher B, Anderson S. Conservative surgery for the management of invasive and noninvasive carcinoma of the breast: NSABP trials. National Surgical Adjuvant Breast and Bowel Project. World J Surg 1994; 18: 63–69
[31] Lyman GH, Temin S, Edge SB et al. Sentinel lymph node biopsy for patients with early-stage breast cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 2014; 32: 1365–1383
[13] Voogd AC, Nielsen M, Peterse JL et al. Differences in risk factors for local
and distant recurrence after breast-conserving therapy or mastectomy
for stage I and II breast cancer: pooled results of two large European randomized trials. J Clin Oncol 2001; 19: 1688–1697
[32] Krag DN, Anderson SJ, Julian TB et al. Sentinel-lymph-node resection
compared with conventional axillary-lymph-node dissection in clinically
node-negative patients with breast cancer: overall survival findings from
the NSABP B‑32 randomised phase 3 trial. Lancet Oncol 2010; 11: 927–
933
[14] De La Cruz L, Moody AM, Tappy EE et al. Overall Survival, Disease-Free
Survival, Local Recurrence, and Nipple-Areolar Recurrence in the Setting
of Nipple-Sparing Mastectomy: A Meta-Analysis and Systematic Review.
Ann Surg Oncol 2015; 22: 3241–3249
[33] Houssami N, Ciatto S, Turner RM et al. Preoperative ultrasound-guided
needle biopsy of axillary nodes in invasive breast cancer: meta-analysis
of its accuracy and utility in staging the axilla. Ann Surg 2011; 254:
243–251
[15] Endara M, Chen D, Verma K et al. Breast reconstruction following nipplesparing mastectomy: a systematic review of the literature with pooled
analysis. Plast Reconstr Surg 2013; 132: 1043–1054
[34] Straver ME, Meijnen P, van Tienhoven G et al. Role of axillary clearance
after a tumor-positive sentinel node in the administration of adjuvant
therapy in early breast cancer. J Clin Oncol 2010; 28: 731–737
[16] Lanitis S, Tekkis PP, Sgourakis G et al. Comparison of skin-sparing mastectomy versus non-skin-sparing mastectomy for breast cancer: a
meta-analysis of observational studies. Ann Surg 2010; 251: 632–639
[35] Giuliano AE, Hunt KK, Ballman KV et al. Axillary dissection vs. no axillary
dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial. JAMA 2011; 305: 569–575
[17] Piper M, Peled AW, Foster RD et al. Total skin-sparing mastectomy: a systematic review of oncologic outcomes and postoperative complications.
Ann Plast Surg 2013; 70: 435–437
[36] Galimberti V, Cole BF, Zurrida S et al. Axillary dissection versus no axillary
dissection in patients with sentinel-node micrometastases (IBCSG 2301): a phase 3 randomised controlled trial. Lancet Oncol 2013; 14:
297–305
Wöckel A et al. Interdisciplinary Screening, Diagnosis, …
Geburtsh Frauenheilk 2018; 78: 1056–1088
1079
GebFra Science | Guideline
[37] Classe JM, Bordes V, Campion L et al. Sentinel lymph node biopsy after
neoadjuvant chemotherapy for advanced breast cancer: results of Ganglion Sentinelle et Chimiotherapie Neoadjuvante, a French prospective
multicentric study. J Clin Oncol 2009; 27: 726–732
[53] START Trialistsʼ Group, Bentzen SM, Agrawal RK, Aird EG et al. The UK
Standardisation of Breast Radiotherapy (START) Trial B of radiotherapy
hypofractionation for treatment of early breast cancer: a randomised trial. Lancet 2008; 371: 1098–1107
[38] Boughey JC, Suman VJ, Mittendorf EA et al. Sentinel lymph node surgery
after neoadjuvant chemotherapy in patients with node-positive breast
cancer: the ACOSOG Z1071 (Alliance) clinical trial. JAMA 2013; 310:
1455–1461
[54] Shaitelman SF, Schlembach PJ, Arzu I et al. Acute and Short-term Toxic
Effects of Conventionally Fractionated vs. Hypofractionated WholeBreast Irradiation: A Randomized Clinical Trial. JAMA Oncol 2015; 1:
931–941
[39] Kuehn T, Bauerfeind I, Fehm T et al. Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy
(SENTINA): a prospective, multicentre cohort study. Lancet Oncol 2013;
14: 609–618
[55] Antonini N, Jones H, Horiot JC et al. Effect of age and radiation dose on
local control after breast conserving treatment: EORTC trial 2288110882. Radiother Oncol 2007; 82: 265–271
[40] Clarke M, Collins R, Darby S et al. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence
and 15-year survival: an overview of the randomised trials. Lancet 2005;
366: 2087–2106
[41] Early Breast Cancer Trialistsʼ Collaborative Group (EBCTCG); Darby S,
McGale P, Correa C et al. Effect of radiotherapy after breast-conserving
surgery on 10-year recurrence and 15-year breast cancer death: metaanalysis of individual patient data for 10,801 women in 17 randomised
trials. Lancet 2011; 378: 1707–1716
[42] Pötter R, Gnant M, Kwasny W et al. Lumpectomy plus tamoxifen or anastrozole with or without whole breast irradiation in women with favorable
early breast cancer. Int J Radiat Oncol Biol Phys 2007; 68: 334–340
[43] Hughes KS, Schnaper LA, Bellon JR et al. Lumpectomy plus tamoxifen
with or without irradiation in women age 70 years or older with early
breast cancer: long-term follow-up of CALGB 9343. J Clin Oncol 2013;
31: 2382–2387
[44] Kunkler IH, Williams LJ, Jack WJ et al. Breast-conserving surgery with or
without irradiation in women aged 65 years or older with early breast
cancer (PRIME II): a randomised controlled trial. Lancet Oncol 2015; 16:
266–273
[45] Blamey RW, Bates T, Chetty U et al. Radiotherapy or tamoxifen after conserving surgery for breast cancers of excellent prognosis: British Association of Surgical Oncology (BASO) II trial. Eur J Cancer 2013; 49: 2294–
2302
[46] Fyles AW, McCready DR, Manchul LA et al. Tamoxifen with or without
breast irradiation in women 50 years of age or older with early breast
cancer. N Engl J Med 2004; 351: 963–970
[47] Kauer-Dorner D, Pötter R, Resch A et al. Partial breast irradiation for locally recurrent breast cancer within a second breast conserving treatment: alternative to mastectomy? Results from a prospective trial. Radiother Oncol 2012; 102: 96–101
[48] Owen JR, Ashton A, Bliss JM et al. Effect of radiotherapy fraction size on
tumour control in patients with early-stage breast cancer after local tumour excision: long-term results of a randomised trial. Lancet Oncol
2006; 7: 467–471
[49] Haviland JS, Owen JR, Dewar JA et al. The UK Standardisation of Breast
Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10-year follow-up results of two randomised controlled trials. Lancet Oncol 2013; 14: 1086–1094
[50] Whelan TJ, Pignol JP, Levine MN et al. Long-term results of hypofractionated radiation therapy for breast cancer. N Engl J Med 2010; 362: 513–
520
[51] Yarnold J, Ashton A, Bliss J et al. Fractionation sensitivity and dose response of late adverse effects in the breast after radiotherapy for early
breast cancer: long-term results of a randomised trial. Radiother Oncol
2005; 75: 9–17
[52] START Trialistsʼ Group; Bentzen SM, Agrawal RK, Aird EG et al. The UK
Standardisation of Breast Radiotherapy (START) Trial A of radiotherapy
hypofractionation for treatment of early breast cancer: a randomised trial. Lancet Oncol 2008; 9: 331–341
1080
[56] Bartelink H, Maingon P, Poortmans P et al. Whole-breast irradiation with
or without a boost for patients treated with breast-conserving surgery
for early breast cancer: 20-year follow-up of a randomised phase 3 trial.
Lancet Oncol 2015; 16: 47–56
[57] Vrieling C, van Werkhoven E, Maingon P et al. Prognostic Factors for Local Control in Breast Cancer After Long-term Follow-up in the EORTC
Boost vs. No Boost Trial: A Randomized Clinical Trial. JAMA Oncol 2017;
3: 42–48
[58] Romestaing P, Lehingue Y, Carrie C et al. Role of a 10-Gy boost in the
conservative treatment of early breast cancer: results of a randomized
clinical trial in Lyon, France. J Clin Oncol 1997; 15: 963–968
[59] Polgár C, Van Limbergen E, Pötter R et al. Patient selection for accelerated partial-breast irradiation (APBI) after breast-conserving surgery:
recommendations of the Groupe Européen de Curiethérapie-European
Society for Therapeutic Radiology and Oncology (GEC-ESTRO) breast
cancer working group based on clinical evidence (2009). Radiother Oncol 2010; 94: 264–273
[60] Polgár C, Fodor J, Major T et al. Breast-conserving therapy with partial or
whole breast irradiation: ten-year results of the Budapest randomized
trial. Radiother Oncol 2013; 108: 197–202
[61] Veronesi U, Orecchia R, Maisonneuve P et al. Intraoperative radiotherapy
versus external radiotherapy for early breast cancer (ELIOT): a randomised controlled equivalence trial. Lancet Oncol 2013; 14: 1269–1277
[62] Vaidya JS, Wenz F, Bulsara M et al. Risk-adapted targeted intraoperative
radiotherapy versus whole-breast radiotherapy for breast cancer: 5-year
results for local control and overall survival from the TARGIT‑A randomised trial. Lancet 2014; 383: 603–613
[63] Strnad V, Ott OJ, Hildebrandt G et al. 5-year results of accelerated partial
breast irradiation using sole interstitial multicatheter brachytherapy versus whole-breast irradiation with boost after breast-conserving surgery
for low-risk invasive and in-situ carcinoma of the female breast: a randomised, phase 3, non-inferiority trial. Lancet 2016; 387: 229–238
[64] Polgár C, Ott OJ, Hildebrandt G et al. Late side-effects and cosmetic results of accelerated partial breast irradiation with interstitial brachytherapy versus whole-breast irradiation after breast-conserving surgery for
low-risk invasive and in-situ carcinoma of the female breast: 5-year results of a randomised, controlled, phase 3 trial. Lancet Oncol 2017; 18:
259–268
[65] EBCTCG (Early Breast Cancer Trialistsʼ Collaborative Group); McGale P,
Taylor C, Correa C et al. Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality:
meta-analysis of individual patient data for 8135 women in 22 randomised trials. Lancet 2014; 383: 2127–2135
[66] Gradishar WJ, Anderson BO, Balassanian R et al. Invasive breast cancer
version 1.2016, NCCN clinical practice guidelines in oncology. J Natl
Compr Canc Netw 2016; 14: 324–354
[67] Wang H, Kong L, Zhang C et al. Should all breast cancer patients with
four or more positive lymph nodes who underwent modified radical
mastectomy be treated with postoperative radiotherapy? A populationbased study. Oncotarget 2016; 7: 75492–75502
[68] Elmore L, Deshpande A, Daly M et al. Postmastectomy radiation therapy
in T3 node-negative breast cancer. J Surg Res 2015; 199: 90–96
Wöckel A et al. Interdisciplinary Screening, Diagnosis, …
Geburtsh Frauenheilk 2018; 78: 1056–1088
[69] Francis SR, Frandsen J, Kokeny KE et al. Outcomes and utilization of postmastectomy radiotherapy for T3N0 breast cancers. Breast 2017; 32:
156–161
[70] Karlsson P, Cole BF, Chua BH et al. Patterns and risk factors for locoregional failures after mastectomy for breast cancer: an International
Breast Cancer Study Group report. Ann Oncol 2012; 23: 2852–2858
[71] Kyndi M, Overgaard M, Nielsen HM et al. High local recurrence risk is not
associated with large survival reduction after postmastectomy radiotherapy in high-risk breast cancer: a subgroup analysis of DBCG 82 b&c.
Radiother Oncol 2009; 90: 74–79
[72] Nagao T, Kinoshita T, Tamura N et al. Locoregional recurrence risk factors in breast cancer patients with positive axillary lymph nodes and the
impact of postmastectomy radiotherapy. Int J Clin Oncol 2013; 18: 54–
61
[73] Danish Breast Cancer Cooperative Group; Nielsen HM, Overgaard M,
Grau C et al. Study of failure pattern among high-risk breast cancer patients with or without postmastectomy radiotherapy in addition to adjuvant systemic therapy: long-term results from the Danish Breast Cancer
Cooperative Group DBCG 82 b and c randomized studies. J Clin Oncol
2006; 24: 2268–2275
[74] Recht A, Comen EA, Fine RE et al. Postmastectomy Radiotherapy: An
American Society of Clinical Oncology, American Society for Radiation
Oncology, and Society of Surgical Oncology Focused Guideline Update.
J Clin Oncol 2016; 34: 4431–4442
[75] Wang H, Zhang C, Kong L et al. Better survival in PMRT of female breast
cancer patients with >5 negative lymph nodes: A population-based
study. Medicine (Baltimore) 2017; 96: e5998
[76] Headon H, Kasem A, Almukbel R et al. Improvement of survival with
postmastectomy radiotherapy in patients with 1–3 positive axillary
lymph nodes: A systematic review and meta-analysis of the current literature. Mol Clin Oncol 2016; 5: 429–436
[77] Valli MC. Controversies in loco-regional treatment: post-mastectomy radiation for pT2-pT3N0 breast cancer arguments in favour. Crit Rev Oncol
Hematol 2012; 84 (Suppl. 1): e70–e74
[78] Overgaard M, Hansen PS, Overgaard J et al. Postoperative radiotherapy
in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy. Danish Breast Cancer Cooperative Group 82b Trial.
N Engl J Med 1997; 337: 949–955
[79] Overgaard M, Jensen MB, Overgaard J et al. Postoperative radiotherapy
in high-risk postmenopausal breast-cancer patients given adjuvant tamoxifen: Danish Breast Cancer Cooperative Group DBCG 82c randomised trial. Lancet 1999; 353: 1641–1648
[80] Rusthoven CG, Rabinovitch RA, Jones BL et al. The impact of postmastectomy and regional nodal radiation after neoadjuvant chemotherapy for
clinically lymph node-positive breast cancer: a National Cancer Database
(NCDB) analysis. Ann Oncol 2016; 27: 818–827
[81] Mamounas EP, Anderson SJ, Dignam JJ et al. Predictors of locoregional
recurrence after neoadjuvant chemotherapy: results from combined
analysis of National Surgical Adjuvant Breast and Bowel Project B‑18
and B‑27. J Clin Oncol 2012; 30: 3960–3966
[82] Kishan AU, McCloskey SA. Postmastectomy radiation therapy after neoadjuvant chemotherapy: review and interpretation of available data.
Ther Adv Med Oncol 2016; 8: 85–97
[83] Kantor O, Pesce C, Singh P et al. Post-mastectomy radiation therapy and
overall survival after neoadjuvant chemotherapy. J Surg Oncol 2017;
115: 668–676. doi:10.1002/jso.24551
[84] Poortmans PM, Collette S, Kirkove C et al. Internal mammary and medial
supraclavicular irradiation in breast cancer. N Engl J Med 2015; 373:
317–327
[85] Thorsen LB, Offersen BV, Danø H et al. DBCG‑IMN: A Population-Based
Cohort Study on the Effect of Internal Mammary Node Irradiation in Early
Node-Positive Breast Cancer. J Clin Oncol 2016; 34: 314–320
Wöckel A et al. Interdisciplinary Screening, Diagnosis, …
[86]
Whelan TJ, Olivotto IA, Parulekar WR et al. Regional nodal irradiation in
early-stage breast cancer. N Engl J Med 2015; 373: 307–316
[87]
Hennequin C, Bossard N, Servagi-Vernat S et al. Ten-year survival results of a randomized trial of irradiation of internal mammary nodes
after mastectomy. Int J Radiat Oncol Biol Phys 2013; 86: 860–866
[88]
Budach W, Bölke E, Kammers K et al. Adjuvant radiation therapy of regional lymph nodes in breast cancer – a meta-analysis of randomized
trials- an update. Radiat Oncol 2015; 10: 258
[89]
Recht A, Edge SB, Solin LJ et al. Postmastectomy radiotherapy: clinical
practice guidelines of the American Society of Clinical Oncology. J Clin
Oncol 2001; 19: 1539–1569
[90]
Yates L, Kirby A, Crichton S et al. Risk factors for regional nodal relapse
in breast cancer patients with one to three positive axillary nodes. Int
J Radiat Oncol Biol Phys 2012; 82: 2093–2103
[91]
Caussa L, Kirova YM, Gault N et al. The acute skin and heart toxicity of a
concurrent association of trastuzumab and locoregional breast radiotherapy including internal mammary chain: a single-institution study.
Eur J Cancer 2011; 47: 65–73
[92]
Shaffer R, Tyldesley S, Rolles M et al. Acute cardiotoxicity with concurrent trastuzumab and radiotherapy including internal mammary chain
nodes: a retrospective single-institution study. Radiother Oncol 2009;
90: 122–126
[93]
Donker M, van Tienhoven G, Straver ME et al. Radiotherapy or surgery
of the axilla after a positive sentinel node in breast cancer
(EORTC10981–22023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trial. Lancet Oncol 2014; 15: 1303–1310
[94]
Gruber G, Cole BF, Castiglione-Gertsch M et al. Extracapsular tumor
spread and the risk of local, axillary and supraclavicular recurrence in
node-positive, premenopausal patients with breast cancer. Ann Oncol
2008; 19: 1393–1401
[95]
Jagsi R, Chadha M, Moni J et al. Radiation field design in the ACOSOG
Z0011 (Alliance) Trial. J Clin Oncol 2014; 32: 3600–3606
[96]
Bartelink H, Rubens RD, van der Schueren E et al. Hormonal therapy
prolongs survival in irradiated locally advanced breast cancer: a European Organization for Research and Treatment of Cancer Randomized
Phase III Trial. J Clin Oncol 1997; 15: 207–215
[97]
Scotti V, Desideri I, Meattini I et al. Management of inflammatory
breast cancer: focus on radiotherapy with an evidence-based approach. Cancer Treat Rev 2013; 39: 119–124
[98]
Bellon JR, Come SE, Gelman RS et al. Sequencing of chemotherapy and
radiation therapy in early-stage breast cancer: updated results of a
prospective randomized trial. J Clin Oncol 2005; 23: 1934–1940
[99]
Hickey BE, Francis D, Lehman MH. Sequencing of chemotherapy and
radiation therapy for early breast cancer. Cochrane Database Syst Rev
2006; (4): CD005212
[100] Hickey BE, Francis DP, Lehman M. Sequencing of chemotherapy and radiotherapy for early breast cancer. Cochrane Database Syst Rev 2013;
(4): CD005212
[101] Pinnarò P, Rambone R, Giordano C et al. Long-term results of a randomized trial on the sequencing of radiotherapy and chemotherapy
in breast cancer. Am J Clin Oncol 2011; 34: 238–244
[102] Chen Z, King W, Pearcey R et al. The relationship between waiting time
for radiotherapy and clinical outcomes: a systematic review of the literature. Radiother Oncol 2008; 87: 3–16
[103] Huang J, Barbera L, Brouwers M et al. Does delay in starting treatment
affect the outcomes of radiotherapy? A systematic review. J Clin Oncol
2003; 21: 555–563
[104] Halyard MY, Pisansky TM, Dueck AC et al. Radiotherapy and adjuvant
trastuzumab in operable breast cancer: tolerability and adverse event
data from the NCCTG Phase III Trial N9831. J Clin Oncol 2009; 27:
2638–2644
Geburtsh Frauenheilk 2018; 78: 1056–1088
1081
GebFra Science | Guideline
[105] Li YF, Chang L, Li WH et al. Radiotherapy concurrent versus sequential
with endocrine therapy in breast cancer: A meta-analysis. Breast 2016;
27: 93–98
[106] Goldhirsch A, Wood WC, Coates AS et al. Strategies for subtypes –
dealing with the diversity of breast cancer: highlights of the St. Gallen
International Expert Consensus on the Primary Therapy of Early Breast
Cancer 2011. Ann Oncol 2011; 22: 1736–1747
[107] Polychemotherapy for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialistsʼ Collaborative Group. Lancet
1998; 352: 930–942
[108] Early Breast Cancer Trialistsʼ Collaborative Group (EBCTCG); Davies C,
Godwin J, Gray R et al. Relevance of breast cancer hormone receptors
and other factors to the efficacy of adjuvant tamoxifen: patient-level
meta-analysis of randomised trials. Lancet 2011; 378: 771–784
[109] Fisher B, Dignam J, Wolmark N et al. Tamoxifen and chemotherapy for
lymph node-negative, estrogen receptor-positive breast cancer. J Natl
Cancer Inst 1997; 89: 1673–1682
[110] The International Breast Cancer Study Group; Thürlimann B, Price KN,
Castiglione M et al. Randomized controlled trial of ovarian function
suppression plus tamoxifen versus the same endocrine therapy plus
chemotherapy: Is chemotherapy necessary for premenopausal women
with node-positive, endocrine-responsive breast cancer? First results
of International Breast Cancer Study Group Trial 11-93. The Breast
2001; 10: 130–138
[111] Burstein HJ, Temin S, Anderson H et al. Adjuvant endocrine therapy for
women with hormone receptor-positive breast cancer: American Society of Clinical Oncology clinical practice guideline focused update.
J Clin Oncol 2014; 32: 2255–2269
[112] Davies C, Pan H, Godwin J et al. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of
oestrogen receptor-positive breast cancer: ATLAS, a randomised trial.
Lancet 2013; 381: 805–816
[113] Gray RG, Rea D, Handley K. aTTom: Long-term effects of continuing
adjuvant tamoxifen to 10 years versus stopping at 5 years in 6,953
women with early breast cancer. J Clin Oncol 2013; 31: 18_suppl, 5-5
[114] Rea DW, Gray RG, Bowden SJ. Overall and subgroup findings of the
aTTom trial: A randomised comparison of continuing adjuvant tamoxifen to 10 years compared to stopping after 5 years in 6953 women
with ER positive or ER untested early breast cancer. Eur J Cancer 2013;
49: S402
[115] Eisen A, Fletcher GG, Gandhi S et al. Optimal Systemic Therapy for Early
Female Breast Cancer. Toronto (ON): Cancer Care Ontario; 2014 Sep
30. Program in Evidence-Based Care Evidence-Based Series No.: 1–21
[122] French Adjuvant Study Group. Benefit of a high-dose epirubicin regimen in adjuvant chemotherapy for node-positive breast cancer patients with poor prognostic factors: 5-year follow-up results of French
Adjuvant Study Group 05 randomized trial. J Clin Oncol 2001; 19: 602–
611
[123] Fumoleau P, Kerbrat P, Romestaing P et al. Randomized trial comparing
six versus three cycles of epirubicin-based adjuvant chemotherapy in
premenopausal, node-positive breast cancer patients: 10-year followup results of the French Adjuvant Study Group 01 trial. J Clin Oncol
2003; 21: 298–305
[124] Swain SM, Jeong JH, Geyer CE jr. et al. Longer therapy, iatrogenic
amenorrhea, and survival in early breast cancer. N Engl J Med 2010;
362: 2053–2065
[125] Bonadonna G, Zambetti M, Valagussa P. Sequential or alternating
doxorubicin and CMF regimens in breast cancer with more than three
positive nodes. Ten-year results. JAMA 1995; 273: 542–547
[126] Citron ML, Berry DA, Cirrincione C et al. Randomized trial of dosedense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment
of node-positive primary breast cancer: first report of Intergroup Trial
C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol 2003; 21:
1431–1439
[127] Eiermann W, Pienkowski T, Crown J et al. Phase III study of doxorubicin/
cyclophosphamide with concomitant versus sequential docetaxel as
adjuvant treatment in patients with human epidermal growth factor
receptor 2-normal, node-positive breast cancer: BCIRG‑005 trial. J Clin
Oncol 2011; 29: 3877–3884
[128] Francis P, Crown J, Di Leo A et al. Adjuvant chemotherapy with sequential or concurrent anthracycline and docetaxel: Breast International
Group 02-98 randomized trial. J Natl Cancer Inst 2008; 100: 121–133
[129] Moebus V, Jackisch C, Lueck HJ et al. Intense dose-dense sequential
chemotherapy with epirubicin, paclitaxel, and cyclophosphamide
compared with conventionally scheduled chemotherapy in high-risk
primary breast cancer: mature results of an AGO phase III study. J Clin
Oncol 2010; 28: 2874–2880
[130] Del Mastro L, De Placido S, Bruzzi P et al. Fluorouracil and dose-dense
chemotherapy in adjuvant treatment of patients with early-stage
breast cancer: an open-label, 2 × 2 factorial, randomised phase 3 trial.
Lancet 2015; 385: 1863–1872
[131] Bria E, Nistico C, Cuppone F et al. Benefit of taxanes as adjuvant chemotherapy for early breast cancer: pooled analysis of 15,500 patients.
Cancer 2006; 106: 2337–2344
[116] Ferguson T, Wilcken N, Vagg R et al. Taxanes for adjuvant treatment of
early breast cancer. Cochrane Database Syst Rev 2007; (4): CD004421
[132] Clavarezza M, Del Mastro L, Venturini M. Taxane-containing chemotherapy in the treatment of early breast cancer patients. Ann Oncol
2006; 17 (Suppl. 7): vii22–vii26
[117] Sparano JA, Zhao F, Martino S et al. Long-Term Follow-Up of the E1199
Phase III Trial Evaluating the Role of Taxane and Schedule in Operable
Breast Cancer. J Clin Oncol 2015; 33: 2353–2360
[133] Estévez LG, Muñoz M, Alvarez I et al. Evidence-based use of taxanes in
the adjuvant setting of breast cancer. A review of randomized phase III
trials. Cancer Treat Rev 2007; 33: 474–483
[118] Early Breast Cancer Trialistsʼ Collaborative Group (EBCTCG); Peto R, Davies C, Godwin J et al. Comparisons between different
polychemotherapy regimens for early breast cancer: meta-analyses of
long-term outcome among 100,000 women in 123 randomised trials.
Lancet 2012; 379: 432–444
[134] Henderson IC, Berry DA, Demetri GD et al. Improved outcomes from
adding sequential Paclitaxel but not from escalating Doxorubicin dose
in an adjuvant chemotherapy regimen for patients with node-positive
primary breast cancer. J Clin Oncol 2003; 21: 976–983
[119] EBM Reviews. Multi-agent chemotherapy for early breast cancer.
Cochrane Database Syst Rev 2003
[120] Budman DR, Berry DA, Cirrincione CT et al. Dose and dose intensity as
determinants of outcome in the adjuvant treatment of breast cancer.
The Cancer and Leukemia Group B. J Natl Cancer Inst 1998; 90: 1205–
1211
[121] Fisher B, Anderson S, Wickerham DL et al. Increased intensification and
total dose of cyclophosphamide in a doxorubicin-cyclophosphamide
regimen for the treatment of primary breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B‑22. J Clin Oncol
1997; 15: 1858–1869
1082
[135] Mamounas EP, Bryant J, Lembersky B et al. Paclitaxel after doxorubicin
plus cyclophosphamide as adjuvant chemotherapy for node-positive
breast cancer: results from NSABP B‑28. J Clin Oncol 2005; 23: 3686–
3696
[136] Roché H, Fumoleau P, Spielmann M et al. Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: the FNCLCC PACS01 Trial. J Clin Oncol 2006; 24: 5664–
5671
[137] Blum JL, Flynn PJ, Yothers G et al. Anthracyclines in Early Breast Cancer:
The ABC Trials-USOR 06-090, NSABP B‑46-I/USOR 07132, and NSABP
B‑49 (NRG Oncology). J Clin Oncol 2017; 35: 2647–2655
Wöckel A et al. Interdisciplinary Screening, Diagnosis, …
Geburtsh Frauenheilk 2018; 78: 1056–1088
[138] Ejlertsen B, Tuxen MK, Jakobsen EH et al. Adjuvant Cyclophosphamide
and Docetaxel With or Without Epirubicin for Early TOP2A-Normal
Breast Cancer: DBCG 07-READ, an Open-Label, Phase III, Randomized
Trial. J Clin Oncol 2017; 35: 2639–2646. doi:10.1200/
JCO.2017.72.3494
[139] Harbeck N, Gluz O, Clemens MR et al. Prospective WSG phase III PlanB
trial: Final analysis of adjuvant 4xEC→4x doc vs. 6x docetaxel/cyclophosphamide in patients with high clinical risk and intermediate-tohigh genomic risk HER2-negative, early breast cancer. J Clin Oncol
2017; 35:15_suppl, 504-504
[140] von Minckwitz G, Untch M, Nüesch E et al. Impact of treatment characteristics on response of different breast cancer phenotypes: pooled
analysis of the German neo-adjuvant chemotherapy trials. Breast Cancer Res Treat 2011; 125: 145–156
[141] Cortazar P, Zhang L, Untch M et al. Pathological complete response
and long-term clinical benefit in breast cancer: the CTNeoBC pooled
analysis. Lancet 2014; 384: 164–172
[142] Kaufmann M, Hortobagyi GN, Goldhirsch A et al. Recommendations
from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: an update. J Clin
Oncol 2006; 24: 1940–1949
[143] Bear HD, Anderson S, Smith RE et al. Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: National Surgical Adjuvant
Breast and Bowel Project Protocol B‑27. J Clin Oncol 2006; 24: 2019–
2027
[144] von Minckwitz G, Blohmer JU, Raab G et al. In vivo chemosensitivityadapted preoperative chemotherapy in patients with early-stage
breast cancer: the GEPARTRIO pilot study. Ann Oncol 2005; 16: 56–63
[145] Petrelli F, Barni S. Meta-analysis of concomitant compared to sequential adjuvant trastuzumab in breast cancer: the sooner the better. Med
Oncol 2012; 29: 503–510
[146] Pfeilschifter J, Diel IJ. Osteoporosis due to cancer treatment: pathogenesis and management. J Clin Oncol 2000; 18: 1570–1593
[147] Gnant M, Mlineritsch B, Schippinger W et al. Endocrine therapy plus
zoledronic acid in premenopausal breast cancer. N Engl J Med 2009;
360: 679–691
[148] Gnant M, Mlineritsch B, Stoeger H et al. Adjuvant endocrine therapy
plus zoledronic acid in premenopausal women with early-stage breast
cancer: 62-month follow-up from the ABCSG‑12 randomised trial. Lancet Oncol 2011; 12: 631–641
[149] Hadji P, Kauka A, Ziller M et al. Effects of zoledronic acid on bone mineral density in premenopausal women receiving neoadjuvant or adjuvant therapies for HR+ breast cancer: the ProBONE II study. Osteoporos Int 2014; 25: 1369–1378
[150] Gnant M, Pfeiler G, Dubsky PC et al. Adjuvant denosumab in breast
cancer (ABCSG‑18): a multicentre, randomised, double-blind,
placebo-controlled trial. Lancet 2015; 386: 433–443
[151] Kalder M, Hans D, Kyvernitakis I et al. Effects of Exemestane and Tamoxifen treatment on bone texture analysis assessed by TBS in comparison with bone mineral density assessed by DXA in women with
breast cancer. J Clin Densitom 2014; 17: 66–71
[152] Hadji P, Asmar L, van Nes JG et al. The effect of exemestane and tamoxifen on bone health within the Tamoxifen Exemestane Adjuvant Multinational (TEAM) trial: a meta-analysis of the US, German, Netherlands,
and Belgium sub-studies. J Cancer Res Clin Oncol 2011; 137: 1015–
1025
[153] Rabaglio M, Sun Z, Price KN et al. Bone fractures among postmenopausal patients with endocrine-responsive early breast cancer treated with
5 years of letrozole or tamoxifen in the BIG 1-98 trial. Ann Oncol 2009;
20: 1489–1498
[154] Greep NC, Giuliano AE, Hansen NM et al. The effects of adjuvant chemotherapy on bone density in postmenopausal women with early
breast cancer. Am J Med 2003; 114: 653–659
Wöckel A et al. Interdisciplinary Screening, Diagnosis, …
[155] Hadji P, Ziller M, Maskow C et al. The influence of chemotherapy on
bone mineral density, quantitative ultrasonometry and bone turnover
in pre-menopausal women with breast cancer. Eur J Cancer 2009; 45:
3205–3212
[156] Kanis JA, Oden A, Johnell O et al. The use of clinical risk factors enhances the performance of BMD in the prediction of hip and osteoporotic fractures in men and women. Osteoporos Int 2007; 18: 1033–
1046
[157] Frost SA, Nguyen ND, Center JR et al. Timing of repeat BMD measurements: development of an absolute risk-based prognostic model.
J Bone Miner Res 2009; 24: 1800–1807
[158] Coleman R, Cameron D, Dodwell D et al. Adjuvant zoledronic acid in
patients with early breast cancer: final efficacy analysis of the AZURE
(BIG 01/04) randomised open-label phase 3 trial. Lancet Oncol 2014;
15: 997–1006
[159] Col NF, Hirota LK, Orr RK et al. Hormone replacement therapy after
breast cancer: a systematic review and quantitative assessment of risk.
J Clin Oncol 2001; 19: 2357–2363
[160] Pantel K, Alix-Panabieres C, Riethdorf S. Cancer micrometastases. Nat
Rev Clin Oncol 2009; 6: 339–351
[161] Wilson C, Holen I, Coleman RE. Seed, soil and secreted hormones: potential interactions of breast cancer cells with their endocrine/paracrine microenvironment and implications for treatment with bisphosphonates. Cancer Treat Rev 2012; 38: 877–889
[162] Domschke C, Diel IJ, Englert S et al. Prognostic value of disseminated
tumor cells in the bone marrow of patients with operable primary
breast cancer: a long-term follow-up study. Ann Surg Oncol 2013; 20:
1865–1871
[163] Banys M, Solomayer EF, Gebauer G et al. Influence of zoledronic acid on
disseminated tumor cells in bone marrow and survival: results of a prospective clinical trial. BMC Cancer 2013; 13: 480
[164] Ben-Aharon I, Vidal L, Rizel S et al. Bisphosphonates in the adjuvant setting of breast cancer therapy – effect on survival: a systematic review
and meta-analysis. PLoS One 2013; 8: e70044
[165] Early Breast Cancer Trialistsʼ Collaborative Group (EBCTCG). Adjuvant
bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials. Lancet 2015; 386: 1353–
1361
[166] Coleman R, Body JJ, Aapro M et al. Bone health in cancer patients:
ESMO Clinical Practice Guidelines. Ann Oncol 2014; 25 (Suppl. 3):
iii124–iii137
[167] Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche
Krebshilfe, AWMF). Supportive Therapie bei onkologischen PatientInnen-Konsultationsfassung, Langversion, 2016, AWMF Registernummer: 032–054OL, 2016. Online: http://leitlinienprogramm-onkologie.
de/Supportive-Therapie.95.0.html; last access: 13.10.2016
[168] Grunfeld E, Dhesy-Thind S, Levine M. Clinical practice guidelines for
the care and treatment of breast cancer: follow-up after treatment
for breast cancer (summary of the 2005 update). CMAJ 2005; 172:
1319–1320
[169] Hauner D, Janni W, Rack B et al. The effect of overweight and nutrition
on prognosis in breast cancer. Dtsch Arztebl Int 2011; 108: 795–801
[170] Voskuil DW, van Nes JG, Junggeburt JM et al. Maintenance of physical
activity and body weight in relation to subsequent quality of life in
postmenopausal breast cancer patients. Ann Oncol 2010; 21: 2094–
2101
[171] Rock CL, Doyle C, Demark-Wahnefried W et al. Nutrition and physical
activity guidelines for cancer survivors. CA Cancer J Clin 2012; 62:
243–274
[172] Cheema BS, Kilbreath SL, Fahey PP et al. Safety and efficacy of progressive resistance training in breast cancer: a systematic review and metaanalysis. Breast Cancer Res Treat 2014; 148: 249–268
Geburtsh Frauenheilk 2018; 78: 1056–1088
1083
GebFra Science | Guideline
[173] Courneya KS, McKenzie DC, Mackey JR et al. Subgroup effects in a randomised trial of different types and doses of exercise during breast
cancer chemotherapy. Br J Cancer 2014; 111: 1718–1725
[193] Lambertini M, Del Mastro L, Pescio MC et al. Cancer and fertility preservation: international recommendations from an expert meeting.
BMC Med 2016; 14: 1
[174] Irwin ML, Cartmel B, Gross CP et al. Randomized exercise trial of aromatase inhibitor-induced arthralgia in breast cancer survivors. J Clin
Oncol 2015; 33: 1104–1111
[194] Gennari A, Costa M, Puntoni M et al. Breast cancer incidence after hormonal treatments for infertility: systematic review and meta-analysis
of population-based studies. Breast Cancer Res Treat 2015; 150: 405–
413
[175] Steindorf K, Schmidt ME, Klassen O et al. Randomized, controlled trial
of resistance training in breast cancer patients receiving adjuvant radiotherapy: results on cancer-related fatigue and quality of life. Ann
Oncol 2014; 25: 2237–2243
[195] Luke B, Brown MB, Missmer SA et al. Assisted reproductive technology
use and outcomes among women with a history of cancer. Hum Reprod 2016; 31: 183–189
[176] Furmaniak AC, Menig M, Markes MH. Exercise for women receiving adjuvant therapy for breast cancer. Cochrane Database Syst Rev 2016;
(9): CD005001
[196] Loibl S, Han SN, von Minckwitz G et al. Treatment of breast cancer during pregnancy: an observational study. Lancet Oncol 2012; 13: 887–
896
[177] Meneses-Echavez JF, Gonzalez-Jimenez E, Ramirez-Velez R. Effects of
supervised exercise on cancer-related fatigue in breast cancer survivors: a systematic review and meta-analysis. BMC Cancer 2015; 15: 77
[197] Loibl S, Schmidt A, Gentilini O et al. Breast Cancer Diagnosed During
Pregnancy: Adapting Recent Advances in Breast Cancer Care for Pregnant Patients. JAMA Oncol 2015; 1: 1145–1153
[178] Bower JE, Bak K, Berger A et al. Screening, assessment, and management of fatigue in adult survivors of cancer: an American Society of
Clinical oncology clinical practice guideline adaptation. J Clin Oncol
2014; 32: 1840–1850
[198] National Toxicology Program. NTP Monograph: Developmental Effects
and Pregnancy Outcomes Associated With Cancer Chemotherapy Use
During Pregnancy. NTP Monogr 2013; (2): i–214
[179] Carayol M, Bernard P, Boiché J et al. Psychological effect of exercise in
women with breast cancer receiving adjuvant therapy: what is the optimal dose needed? Ann Oncol 2013; 24: 291–300
[180] Mishra SI, Scherer RW, Geigle PM et al. Exercise interventions on
health-related quality of life for cancer survivors. Cochrane Database
Syst Rev 2012; (8): CD007566
[199] Zagouri F, Sergentanis TN, Chrysikos D et al. Trastuzumab administration during pregnancy: a systematic review and meta-analysis. Breast
Cancer Res Treat 2013; 137: 349–357
[200] Del Mastro L, Rossi G, Lambertini M et al. New insights on the role of
luteinizing hormone releasing hormone agonists in premenopausal
early breast cancer patients. Cancer Treat Rev 2016; 42: 18–23
[181] Streckmann F, Kneis S, Leifert JA et al. Exercise program improves therapy-related side-effects and quality of life in lymphoma patients
undergoing therapy. Ann Oncol 2014; 25: 493–499
[201] Vitek WS, Shayne M, Hoeger K et al. Gonadotropin-releasing hormone
agonists for the preservation of ovarian function among women with
breast cancer who did not use tamoxifen after chemotherapy: a systematic review and meta-analysis. Fertil Steril 2014; 102: 808–815.e1
[182] Keilani M, Hasenoehrl T, Neubauer M et al. Resistance exercise and secondary lymphedema in breast cancer survivors – a systematic review.
Support Care Cancer 2016; 24: 1907–1916
[202] Moore HC, Unger JM, Phillips KA et al. Goserelin for ovarian protection
during breast-cancer adjuvant chemotherapy. N Engl J Med 2015; 372:
923–932
[183] Nelson NL. Breast Cancer-Related Lymphedema and Resistance Exercise: A Systematic Review. J Strength Cond Res 2016; 30: 2656–2665
[203] Del Mastro L, Boni L, Michelotti A et al. Effect of the gonadotropin-releasing hormone analogue triptorelin on the occurrence of chemotherapy-induced early menopause in premenopausal women with breast
cancer: a randomized trial. JAMA 2011; 306: 269–276
[184] Bok SK, Jeon Y, Hwang PS. Ultrasonographic Evaluation of the Effects
of Progressive Resistive Exercise in Breast Cancer-Related Lymphedema. Lymphat Res Biol 2016; 14: 18–24
[185] Letellier ME, Towers A, Shimony A et al. Breast cancer-related lymphedema: a randomized controlled pilot and feasibility study. Am J Phys
Med Rehabil 2014; 93: 751–759; quiz 760–761
[186] Cormie P, Galvão DA, Spry N et al. Neither heavy nor light load resistance exercise acutely exacerbates lymphedema in breast cancer survivor. Integr Cancer Ther 2013; 12: 423–432
[187] Cormie P, Pumpa K, Galvão DA et al. Is it safe and efficacious for women with lymphedema secondary to breast cancer to lift heavy weights
during exercise: a randomised controlled trial. J Cancer Surviv 2013; 7:
413–424
[188] Runowicz CD, Leach CR, Henry NL et al. American Cancer society/
American society of clinical oncology breast Cancer survivorship care
guideline. CA Cancer J Clin 2016; 66: 43–73
[189] Nechuta S, Chen WY, Cai H et al. A pooled analysis of post-diagnosis
lifestyle factors in association with late estrogen-receptor-positive
breast cancer prognosis. Int J Cancer 2016; 138: 2088–2097
[190] Azim HA jr., Kroman N, Paesmans M et al. Prognostic impact of pregnancy after breast cancer according to estrogen receptor status: a
multicenter retrospective study. J Clin Oncol 2013; 31: 73–79
[191] Azim HA jr., Santoro L, Pavlidis N et al. Safety of pregnancy following
breast cancer diagnosis: a meta-analysis of 14 studies. Eur J Cancer
2011; 47: 74–83
[192] Goldrat O, Kroman N, Peccatori FA et al. Pregnancy following breast
cancer using assisted reproduction and its effect on long-term outcome. Eur J Cancer 2015; 51: 1490–1496
1084
[204] Lambertini M, Boni L, Michelotti A et al. Ovarian Suppression With Triptorelin During Adjuvant Breast Cancer Chemotherapy and Long-term
Ovarian Function, Pregnancies, and Disease-Free Survival: A Randomized Clinical Trial. JAMA 2015; 314: 2632–2640
[205] Gerber B, von Minckwitz G, Stehle H et al. Effect of luteinizing hormone-releasing hormone agonist on ovarian function after modern
adjuvant breast cancer chemotherapy: the GBG 37 ZORO study. J Clin
Oncol 2011; 29: 2334–2341
[206] Munster PN, Moore AP, Ismail-Khan R et al. Randomized trial using gonadotropin-releasing hormone agonist triptorelin for the preservation
of ovarian function during (neo)adjuvant chemotherapy for breast
cancer. J Clin Oncol 2012; 30: 533–538
[207] Kalsi T, Babic-Illman G, Ross PJ et al. The impact of comprehensive geriatric assessment interventions on tolerance to chemotherapy in older
people. Br J Cancer 2015; 112: 1435–1444
[208] Hall DE, Arya S, Schmid KK et al. Association of a Frailty Screening Initiative With Postoperative Survival at 30, 180, and 365 Days. JAMA
Surg 2017; 152: 233–240
[209] Le Saux O, Ripamonti B, Bruyas A et al. Optimal management of breast
cancer in the elderly patient: current perspectives. Clin Interv Aging
2015; 10: 157–174
[210] Decoster L, Van Puyvelde K, Mohile S et al. Screening tools for multidimensional health problems warranting a geriatric assessment in older
cancer patients: an update on SIOG recommendations†. Ann Oncol
2015; 26: 288–300
Wöckel A et al. Interdisciplinary Screening, Diagnosis, …
Geburtsh Frauenheilk 2018; 78: 1056–1088
[211] Clough-Gorr KM, Stuck AE, Thwin SS et al. Older breast cancer survivors: geriatric assessment domains are associated with poor tolerance
of treatment adverse effects and predict mortality over 7 years of follow-up. J Clin Oncol 2010; 28: 380–386
[212] Mislang AR, Biganzoli L. Adjuvant Systemic Therapy in Older Breast
Cancer Women: Can We Optimize the Level of Care? Cancers (Basel)
2015; 7: 1191–1214
[213] Biganzoli L, Wildiers H, Oakman C et al. Management of elderly patients with breast cancer: updated recommendations of the International Society of Geriatric Oncology (SIOG) and European Society of
Breast Cancer Specialists (EUSOMA). Lancet Oncol 2012; 13: e148–
e160
[214] Thavarajah N, Menjak I, Trudeau M et al. Towards an optimal multidisciplinary approach to breast cancer treatment for older women. Can
Oncol Nurs J 2015; 25: 384–408
[215] Morgan J, Wyld L, Collins KA et al. Surgery versus primary endocrine
therapy for operable primary breast cancer in elderly women (70 years
plus). Cochrane Database Syst Rev 2014; (5): CD004272. doi:10.1002/
14651858.CD004272.pub3
[216] Christiansen P, Bjerre K, Ejlertsen B et al. Mortality rates among earlystage hormone receptor-positive breast cancer patients: a populationbased cohort study in Denmark. J Natl Cancer Inst 2011; 103: 1363–
1372
[217] Lange M, Heutte N, Rigal O et al. Decline in Cognitive Function in Older
Adults With Early-Stage Breast Cancer After Adjuvant Treatment. Oncologist 2016; 21: 1337–1348. doi:10.1634/theoncologist.2016-0014
[218] Ono M, Ogilvie JM, Wilson JS et al. A meta-analysis of cognitive impairment and decline associated with adjuvant chemotherapy in women
with breast cancer. Front Oncol 2015; 5: 59
[219] Jones S, Holmes FA, OʼShaughnessy J et al. Docetaxel With Cyclophosphamide Is Associated With an Overall Survival Benefit Compared With
Doxorubicin and Cyclophosphamide: 7-Year Follow-Up of US Oncology
Research Trial 9735. J Clin Oncol 2009; 27: 1177–1183
[220] Perrone F, Nuzzo F, Di Rella F et al. Weekly docetaxel versus CMF as adjuvant chemotherapy for older women with early breast cancer: final
results of the randomized phase III ELDA trial. Ann Oncol 2015; 26:
675–682
[221] Biganzoli L, Aapro M, Loibl S et al. Taxanes in the treatment of breast
cancer: Have we better defined their role in older patients? A position
paper from a SIOG Task Force. Cancer Treat Rev 2016; 43: 19–26
[222] Muss HB, Berry DA, Cirrincione CT et al. Adjuvant chemotherapy in older women with early-stage breast cancer. N Engl J Med 2009; 360:
2055–2065
[223] Freyer G, Campone M, Peron J et al. Adjuvant docetaxel/cyclophosphamide in breast cancer patients over the age of 70: results of an observational study. Crit Rev Oncol Hematol 2011; 80: 466–473
[224] Loibl S, von Minckwitz G, Harbeck N et al. Clinical feasibility of (neo)adjuvant taxane-based chemotherapy in older patients: analysis of
> 4,500 patients from four German randomized breast cancer trials.
Breast Cancer Res 2008; 10: R77
[225] Swain SM, Whaley FS, Ewer MS. Congestive heart failure in patients
treated with doxorubicin: a retrospective analysis of three trials. Cancer 2003; 97: 2869–2879
[226] Freedman RA, Seisler DK, Foster JC et al. Risk of acute myeloid leukemia and myelodysplastic syndrome among older women receiving anthracycline-based adjuvant chemotherapy for breast cancer on Modern Cooperative Group Trials (Alliance A151511). Breast Cancer Res
Treat 2017; 161: 363–373
[227] Pinder MC, Duan Z, Goodwin JS et al. Congestive heart failure in older
women treated with adjuvant anthracycline chemotherapy for breast
cancer. J Clin Oncol 2007; 25: 3808–3815
Wöckel A et al. Interdisciplinary Screening, Diagnosis, …
[228] Dall P, Lenzen G, Göhler T et al. Trastuzumab in the treatment of elderly
patients with early breast cancer: Results from an observational study
in Germany. J Geriatr Oncol 2015; 6: 462–469
[229] Brollo J, Curigliano G, Disalvatore D et al. Adjuvant trastuzumab in elderly with HER‑2 positive breast cancer: a systematic review of randomized controlled trials. Cancer Treat Rev 2013; 39: 44–50
[230] Jones SE, Savin MA, Holmes FA et al. Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide
as adjuvant therapy for operable breast cancer. J Clin Oncol 2006; 24:
5381–5387
[231] Dang C, Guo H, Najita J et al. Cardiac Outcomes of Patients Receiving
Adjuvant Weekly Paclitaxel and Trastuzumab for Node-Negative,
ERBB2-Positive Breast Cancer. JAMA Oncol 2016; 2: 29–36
[232] Tolaney SM, Barry WT, Dang CT et al. Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer. N Engl J Med
2015; 372: 134–141
[233] Castro E, Goh C, Olmos D et al. Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and
poor survival outcomes in prostate cancer. J Clin Oncol 2013; 31:
1748–1757
[234] Bundesinstitut für Arzneimittel und Medizinprodukte (BfArM, Bonn);
Paul-Ehrlich-Institut (PEI, Langen). BfArM Bulletin zur Arzneimittelsicherheit. 2010. Online: https://www.bfarm.de/DE/Arzneimittel/
Pharmakovigilanz/Bulletin/_node.html
[235] Deutsch M. Repeat high-dose external beam irradiation for in-breast
tumor recurrence after previous lumpectomy and whole breast irradiation. Int J Radiat Oncol Biol Phys 2002; 53: 687–691
[236] Haffty BG, Reiss M, Beinfield M et al. Ipsilateral breast tumor recurrence as a predictor of distant disease: implications for systemic therapy at the time of local relapse. J Clin Oncol 1996; 14: 52–57
[237] Kurtz JM, Jacquemier J, Amalric R et al. Is breast conservation after local recurrence feasible? Eur J Cancer 1991; 27: 240–244
[238] Whelan T, Clark R, Roberts R et al. Ipsilateral breast tumor recurrence
postlumpectomy is predictive of subsequent mortality: results from a
randomized trial. Investigators of the Ontario Clinical Oncology Group.
Int J Radiat Oncol Biol Phys 1994; 30: 11–16
[239] Fossati R, Confalonieri C, Torri V et al. Cytotoxic and hormonal treatment for metastatic breast cancer: a systematic review of published
randomized trials involving 31,510 women. J Clin Oncol 1998; 16:
3439–3460
[240] Stockler M, Wilcken N, Ghersi D, Simes RJ. The management of advanced breast cancer: systemic reviews of randomised controlled trials
regarding the use of cytotoxic chemotherapy and endocrine therapy.
Woolloomooloo: NHMRC National Breast Cancer Centre; 1997
[241] Stockler M, Wilcken NR, Ghersi D et al. Systematic reviews of chemotherapy and endocrine therapy in metastatic breast cancer. Cancer
Treat Rev 2000; 26: 151–168
[242] Rugo HS, Rumble RB, Macrae E et al. Endocrine Therapy for Hormone
Receptor-Positive Metastatic Breast Cancer: American Society of Clinical Oncology Guideline. J Clin Oncol 2016; 34: 3069–3103
[243] Partridge AH, Rumble RB, Carey LA et al. Chemotherapy and targeted
therapy for women with human epidermal growth factor receptor 2negative (or unknown) advanced breast cancer: American Society of
Clinical Oncology Clinical Practice Guideline. J Clin Oncol 2014; 32:
3307–3329
[244] Sledge GW jr., Hu P, Falkson G et al. Comparison of chemotherapy with
chemohormonal therapy as first-line therapy for metastatic, hormonesensitive breast cancer: An Eastern Cooperative Oncology Group study.
J Clin Oncol 2000; 18: 262–266
[245] Klijn JG, Blamey RW, Boccardo F et al. Combined tamoxifen and luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist alone in premenopausal advanced breast cancer: a meta-analysis
of four randomized trials. J Clin Oncol 2001; 19: 343–353
Geburtsh Frauenheilk 2018; 78: 1056–1088
1085
GebFra Science | Guideline
[246] National Breast and Ovarian Cancer Centre. Recommendations for follow-up of women with early breast cancer. SurryHills, NSW: National
Breast and Ovarian Cancer Centre; 2010. Online: https://guidelines.
canceraustralia.gov.au/guidelines/early_breast_cancer/
[262] Giordano SH, Temin S, Kirshner JJ et al. Systemic therapy for patients
with advanced human epidermal growth factor receptor 2-positive
breast cancer: American Society of Clinical Oncology clinical practice
guideline. J Clin Oncol 2014; 32: 2078–2099
[247] Taylor CW, Green S, Dalton WS et al. Multicenter randomized clinical
trial of goserelin versus surgical ovariectomy in premenopausal patients with receptor-positive metastatic breast cancer: an intergroup
study. J Clin Oncol 1998; 16: 994–999
[263] Balduzzi S, Mantarro S, Guarneri V et al. Trastuzumab-containing regimens for metastatic breast cancer. Cochrane Database Syst Rev 2014;
(6): CD006242
[248] Loibl S, Turner NC, Ro J et al. Palbociclib (PAL) in combination with fulvestrant (F) in pre-/peri-menopausal (PreM) women with metastatic
breast cancer (MBC) and prior progression on endocrine therapy – results from Paloma-3. J Clin Oncol 2016; 34 (Suppl.): Abstr. 524
[264] Kalkanis SN, Kondziolka D, Gaspar LE et al. The role of surgical resection in the management of newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guideline. J Neurooncol 2010; 96: 33–43
[249] Ellis M, Hayes D, Lippman M. Treatment of metastatic breast cancer.
Cancer 2000; 2000: 749–797
[265] Patchell RA, Tibbs PA, Walsh JW et al. A randomized trial of surgery in
the treatment of single metastases to the brain. N Engl J Med 1990;
322: 494–500
[250] Hayes DF, Henderson IC, Shapiro CL. Treatment of metastatic breast
cancer: present and future prospects. Semin Oncol 1995; 22 (2
Suppl. 5): 5–19; discussion 19–21
[266] Vecht CJ, Haaxma-Reiche H, Noordijk EM et al. Treatment of single
brain metastasis: radiotherapy alone or combined with neurosurgery?
Ann Neurol 1993; 33: 583–590
[251] Mouridsen H, Gershanovich M, Sun Y et al. Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women
with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group. J Clin Oncol 2001; 19: 2596–
2606
[267] Patchell RA, Tibbs PA, Regine WF et al. Postoperative radiotherapy in
the treatment of single metastases to the brain: a randomized trial.
JAMA 1998; 280: 1485–1489
[252] Mouridsen H, Sun Y, Gershanovich M et al. First-line therapy with letrozole (femara®) for advanced breast cancer prolongs time to worsening
of Karnofsky Performance Status compared with tamoxifen. Breast
Cancer Res Treat 2001; 69: 185. doi:10.1023/A:1017475415273
[253] Dear RF, McGeechan K, Jenkins MC et al. Combination versus sequential single agent chemotherapy for metastatic breast cancer. Cochrane
Database Syst Rev 2013; (12): CD008792
[254] Sledge GW, Neuberg D, Bernardo P et al. Phase III trial of doxorubicin,
paclitaxel, and the combination of doxorubicin and paclitaxel as frontline chemotherapy for metastatic breast cancer: an intergroup trial
(E1193). J Clin Oncol 2003; 21: 588–592
[255] Miller K, Wang M, Gralow J et al. Paclitaxel plus bevacizumab versus
paclitaxel alone for metastatic breast cancer. N Engl J Med 2007; 357:
2666–2676
[256] Gray R, Bhattacharya S, Bowden C et al. Independent review of E2100:
a phase III trial of bevacizumab plus paclitaxel versus paclitaxel in women with metastatic breast cancer. J Clin Oncol 2009; 27: 4966–4972
[257] Robert NJ, Diéras V, Glaspy J et al. RIBBON‑1: randomized, doubleblind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth
factor receptor 2–negative, locally recurrent or metastatic breast cancer. J Clin Oncol 2011; 29: 1252–1260
[258] Welt A, Marschner N, Lerchenmueller C et al. Capecitabine and bevacizumab with or without vinorelbine in first-line treatment of HER2/neunegative metastatic or locally advanced breast cancer: final efficacy
and safety data of the randomised, open-label superiority phase 3
CARIN trial. Breast Cancer Res Treat 2016; 156: 97–107
[259] Lang I, Brodowicz T, Ryvo L et al. Bevacizumab plus paclitaxel versus
bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer: interim efficacy results of the randomised, open-label, non-inferiority, phase 3 TURANDOT trial. Lancet Oncol 2013; 14: 125–133
[260] Zielinski C, Láng I, Inbar M et al. Bevacizumab plus paclitaxel versus
bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer (TURANDOT): primary endpoint results
of a randomised, open-label, non-inferiority, phase 3 trial. Lancet Oncol 2016; 17: 1230–1239
[261] Carrick S, Parker S, Wilcken N et al. Single agent versus combination
chemotherapy for metastatic breast cancer. Cochrane Database Syst
Rev 2005; (2): CD003372
1086
[268] Kondziolka D, Patel A, Lunsford LD et al. Stereotactic radiosurgery plus
whole brain radiotherapy versus radiotherapy alone for patients with
multiple brain metastases. Int J Radiat Oncol Biol Phys 1999; 45: 427–
434
[269] Andrews DW, Scott CB, Sperduto PW et al. Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with
one to three brain metastases: phase III results of the RTOG 9508 randomised trial. Lancet 2004; 363: 1665–1672
[270] Aoyama H, Shirato H, Tago M et al. Stereotactic radiosurgery plus
whole-brain radiation therapy vs. stereotactic radiosurgery alone for
treatment of brain metastases: a randomized controlled trial. JAMA
2006; 295: 2483–2491
[271] Chang EL, Wefel JS, Hess KR et al. Neurocognition in patients with brain
metastases treated with radiosurgery or radiosurgery plus whole-brain
irradiation: a randomised controlled trial. Lancet Oncol 2009; 10:
1037–1044
[272] Kocher M, Soffietti R, Abacioglu U et al. Adjuvant whole-brain radiotherapy versus observation after radiosurgery or surgical resection of
one to three cerebral metastases: results of the EORTC 22952-26001
study. J Clin Oncol 2011; 29: 134–141
[273] Brown PD, Jaeckle K, Ballman KV et al. Effect of Radiosurgery Alone vs.
Radiosurgery With Whole Brain Radiation Therapy on Cognitive Function in Patients With 1 to 3 Brain Metastases: A Randomized Clinical
Trial. JAMA 2016; 316: 401–409
[274] Li XP, Meng ZQ, Guo WJ et al. Treatment for liver metastases from
breast cancer: results and prognostic factors. World J Gastroenterol
2005; 11: 3782–3787
[275] Mariani P, Servois V, De Rycke Y et al. Liver metastases from breast cancer: Surgical resection or not? A case-matched control study in highly
selected patients. Eur J Surg Oncol 2013; 39: 1377–1383
[276] Taşçi Y, Aksoy E, Taşkın HE et al. A comparison of laparoscopic radiofrequency ablation versus systemic therapy alone in the treatment of
breast cancer metastasis to the liver. HPB (Oxford) 2013; 15: 789–793
[277] Fairhurst K, Leopardi L, Satyadas T et al. The safety and effectiveness of
liver resection for breast cancer liver metastases: A systematic review.
Breast 2016; 30: 175–184
[278] Sadot E, Lee SY, Sofocleous CT et al. Hepatic Resection or Ablation for
Isolated Breast Cancer Liver Metastasis: A Case-control Study With
Comparison to Medically Treated Patients. Ann Surg 2016; 264: 147–
154
[279] Ruiz A, Wicherts DA, Sebagh M et al. Predictive Profile-Nomogram for
Liver Resection for Breast Cancer Metastases: An Aggressive Approach
with Promising Results. Ann Surg Oncol 2017; 24: 535–545
Wöckel A et al. Interdisciplinary Screening, Diagnosis, …
Geburtsh Frauenheilk 2018; 78: 1056–1088
[280] Ruiz A, Castro-Benitez C, Sebagh M et al. Repeat Hepatectomy for
Breast Cancer Liver Metastases. Ann Surg Oncol 2015; 22 (Suppl. 3):
S1057–S1066
[285] Spolverato G, Vitale A, Bagante F et al. Liver Resection for Breast Cancer Liver Metastases: A Cost-utility Analysis. Ann Surg 2017; 265: 792–
799. doi:10.1097/SLA.0000000000001715
[281] Zhou JH, Rosen D, Andreou A et al. Residual tumor thickness at the tumor-normal tissue interface predicts the recurrence-free survival in
patients with liver metastasis of breast cancer. Ann Diagn Pathol
2014; 18: 266–270
[286] Fan J, Chen D, Du H et al. Prognostic factors for resection of isolated
pulmonary metastases in breast cancer patients: a systematic review
and meta-analysis. J Thorac Dis 2015; 7: 1441–1451
[282] Polistina F, Costantin G, Febbraro A et al. Aggressive treatment for hepatic metastases from breast cancer: results from a single center.
World J Surg 2013; 37: 1322–1332
[287] Meimarakis G, Rüttinger D, Stemmler J et al. Prolonged overall survival
after pulmonary metastasectomy in patients with breast cancer. Ann
Thorac Surg 2013; 95: 1170–1180
[288] Kycler W, Laski P. Surgical approach to pulmonary metastases from
breast cancer. Breast J 2012; 18: 52–57
[283] van Walsum GA, de Ridder JA, Verhoef C et al. Resection of liver metastases in patients with breast cancer: survival and prognostic factors.
Eur J Surg Oncol 2012; 38: 910–917
[289] García-Yuste M, Cassivi S, Paleru C. Pulmonary metastasectomy in
breast cancer. J Thorac Oncol 2010; 5: S170–S171
[284] Abbott DE, Brouquet A, Mittendorf EA et al. Resection of liver metastases from breast cancer: estrogen receptor status and response to
chemotherapy before metastasectomy define outcome. Surgery
2012; 151: 710–716
[290] Yhim HY, Han SW, Oh DY et al. Prognostic factors for recurrent breast
cancer patients with an isolated, limited number of lung metastases
and implications for pulmonary metastasectomy. Cancer 2010; 116:
2890–2901
[291] Clive AO, Jones HE, Bhatnagar R et al. Interventions for the management of malignant pleural effusions: a network meta-analysis. Cochrane Database Syst Rev 2016; (5): CD010529
Wöckel A et al. Interdisciplinary Screening, Diagnosis, …
Geburtsh Frauenheilk 2018; 78: 1056–1088
1087
GebFra Science | Guideline
Guideline Program
Editors
Leading Professional Medical Associations
German Society of Gynecology and Obstetrics
(Deutsche Gesellschaft für Gynäkologie
und Geburtshilfe e. V. [DGGG])
Head Office of DGGG and Professional Societies
Hausvogteiplatz 12, DE-10117 Berlin
info@dggg.de
http://www.dggg.de/
President of DGGG
Prof. Dr. Anton Scharl
Direktor der Frauenkliniken
Klinikum St. Marien Amberg
Mariahilfbergweg 7, DE-92224 Amberg
Kliniken Nordoberpfalz AG
Söllnerstraße 16, DE-92637 Weiden
DGGG Guidelines Representatives
Austrian Society of Gynecology and Obstetrics
(Österreichische Gesellschaft für Gynäkologie
und Geburtshilfe [OEGGG])
Innrain 66A, AT-6020 Innsbruck
stephanie.leutgeb@oeggg.at
http://www.oeggg.at
President of OEGGG
Prof. Dr. med. Petra Kohlberger
Universitätsklinik für Frauenheilkunde Wien
Währinger Gürtel 18–20, AT-1180 Wien
OEGGG Guidelines Representatives
Prof. Dr. med. Karl Tamussino
Universitätsklinik für Frauenheilkunde und Geburtshilfe Graz
Auenbruggerplatz 14, AT-8036 Graz
Prof. Dr. med. Matthias W. Beckmann
Universitätsklinikum Erlangen, Frauenklinik
Universitätsstraße 21–23, DE-91054 Erlangen
Prof. Dr. med. Hanns Helmer
Universitätsklinik für Frauenheilkunde Wien
Währinger Gürtel 18–20, AT-1090 Wien
Prof. Dr. med. Erich-Franz Solomayer
Universitätsklinikum des Saarlandes
Geburtshilfe und Reproduktionsmedizin
Kirrberger Straße, Gebäude 9, DE-66421 Homburg
gynécologie
suisse
Guidelines Coordination
Dr. med. Paul Gaß, Christina Meixner
Universitätsklinikum Erlangen, Frauenklinik
Universitätsstraße 21–23, DE-91054 Erlangen
fk-dggg-leitlinien@uk-erlangen.de
http://www.dggg.de/leitlinienstellungnahmen
Swiss Society of Gynecology and Obstetrics
(Schweizerische Gesellschaft für Gynäkologie
und Geburtshilfe [SGGG])
Gynécologie Suisse SGGG
Altenbergstraße 29, Postfach 6, CH-3000 Bern 8
sekretariat@sggg.ch
http://www.sggg.ch/
President of SGGG
Dr. med. David Ehm
FMH für Geburtshilfe und Gynäkologie
Nägeligasse 13, CH-3011 Bern
SGGG Guidelines Representatives
Prof. Dr. med. Daniel Surbek
Universitätsklinik für Frauenheilkunde
Geburtshilfe und feto-maternale Medizin
Inselspital Bern
Effingerstraße 102, CH-3010 Bern
Prof. Dr. med. René Hornung
Kantonsspital St. Gallen, Frauenklinik
Rorschacher Straße 95, CH-9007 St. Gallen
1088
Wöckel A et al. Interdisciplinary Screening, Diagnosis, …
Geburtsh Frauenheilk 2018; 78: 1056–1088